Podcasts about regulatory

Dean's Chat hosts, Drs. Jensen and Richey, welcome Dr. Dyane Tower to Dean's Chat. This episode is sponsored by the American Podiatric Medical Association (APMA)! Dyane Tower, DPM, MPH, MS, CAE is a nationally recognized leader in podiatric medicine and healthcare administration, currently serving as Medical Director and Vice President of Clinical Affairs for the American Podiatric Medical Association (APMA). With a unique blend of clinical training and executive leadership, Dr. Tower plays a pivotal role in shaping national clinical policy, professional standards, and advocacy efforts for the podiatric profession. She holds the degrees of Doctor of Podiatric Medicine degree from the Scholl College of Podiatric Medicine, and completed her 3 year residency at the North Coloroado Podiatric Medicine Surgery program. Her background highlights advanced expertise in organizational governance, strategy, and healthcare leadership. Her interdisciplinary background allows her to bridge clinical practice, public health, and national-level professional advocacy. At APMA, Dr. Tower oversees: • Clinical policy and professional practice standards • Clinical education and evidence-based guidelines • Regulatory affairs and federal advocacy • Public health integration and interdisciplinary collaboration Dr. Tower is widely respected for her strategic vision, clarity of communication, and deep commitment to advancing podiatric medicine at a national level. As a featured guest on Dean's Chat, she provides expert insight into healthcare policy, clinical governance, professional advocacy, and the future direction of the podiatric profession. Beyond her executive leadership, Dr. Tower is known for her mentorship, national speaking engagements, and ongoing efforts to elevate the voice and visibility of podiatric physicians within the broader healthcare ecosystem. Enjoy!

REGULATING ARTIFICIAL INTELLIGENCE Colleague Kevin Frazier. Kevin Frazier continues, warning against a "waterfall of regulation" by states and advocating for "regulatory sandboxes" to allow experimentation. NUMBER 8 NOVEMBER 1955

EU REGULATION VS. US GROWTH Colleague Michael Toth. Michael Toth critiques the European Union's"regulatory imperialism" and contrasts it with the economic growth of the US. NUMBER 4 1935 BRUSSELS

Graham Rigby is the President and CEO of the American Herbal Products Association (AHPA), the leading trade association for the herbal products industry. With 20 years of experience across startups and industry leadership—including serving as Chief Innovation Officer at Care/of—Graham has helped shape how modern supplement brands navigate regulation, formulation, and go-to-market strategy.In this episode of DTC Pod, Graham shares what it actually takes to launch and scale a supplement brand without getting burned by regulators. He breaks down exactly where the line is between claims that sell and claims that get you in trouble, why so many founders get blindsided by FDA and FTC enforcement, and how to work with contract manufacturers when you're just starting out. Graham also gets into the real opportunity in supplements right now—why clinical trials cost 90% less than they did two decades ago, how AI is changing the formulation game, and why a $70 billion market growing at 6.5% still has plenty of room for new entrants. Plus, his take on the brands that are doing it right, from AG1 to Ritual, and what founders can learn from their playbooks.Episode brought to you by StordInteract with other DTC experts and access our monthly fireside chats with industry leaders on DTC Pod Slack.On this episode of DTC Pod, we cover:1. The evolution and growth of the herbal supplement industry2. Key regulatory milestones: DSHEA, GMPs, and FDA compliance for supplements3. What founders must do to stay compliant when launching a supplement brand4. The distinction between pharmaceuticals, dietary supplements, and nutraceuticals5. Marketing, claims, and the importance of substantiation6. Emerging opportunities with clinical trials and claim innovation7. DTC, Amazon, TikTok, and brick-and-mortar distribution channels for wellness brands8. The practicalities and risks of supplement retail (and when to scale beyond DTC)9. Practitioner and non-traditional channels for supplement sales10. How Ingredient AI, Infinite Garden, and other platforms are applying AI to supplements11. Content creators, credentialed doctors, and the new face of trusted health advice12. The role of diagnostics, wearables, and personalization in driving supplement trends13. Growth outlook: Why the supplement market is just getting startedTimestamps00:00 Intro to DTC POD and Graham Rigby02:25 20 years of supplements: Startup vs. regulatory side03:00 The exponential growth of the herbal products market04:44 Regulatory basics: DSHEA, FDA oversight, and GMPs explained07:14 How AHPA helps brands navigate compliance and education08:03 Launching a supplement brand: Key compliance steps and best practices10:00 FDA's post-market regulatory process and founder responsibilities13:04 Supplements vs. pharmaceuticals: Safety, claims, and approvals17:32 Telling stories and using clinical research for marketing claims20:00 What marketers can and cannot say: Health vs. disease claims22:04 Substantiating claims and the importance of compliance for growth24:31 Label vs. online claims: How rules apply to different channels27:02 DTC vs. Amazon, TikTok, and expanding to retail and practitioner channels30:19 The risks and rewards of brick-and-mortar expansion35:14 AI and technology's role in supplement industry efficiency and safety40:47 The rise of content creators and doctors shaping supplement education46:34 Diagnostics, wearables, and the future of personalized wellness51:13 Supplement industry outlook and advice for emerging brands52:25 How to connect with Graham and AHPA, and upcoming founder programsShow notes powered by CastmagicPast guests & brands on DTC Pod include Gilt, PopSugar, Glossier, MadeIN, Prose, Bala, P.volve, Ritual, Bite, Oura, Levels, General Mills, Mid Day Squares, Prose, Arrae, Olipop, Ghia, Rosaluna, Form, Uncle Studios & many more.  Additional episodes you might like:• #175 Ariel Vaisbort - How OLIPOP Runs Influencer, Community, & Affiliate Growth• #184 Jake Karls, Midday Squares - Turning Your Brand Into The Influencer With Content• #205 Kasey Stewart: Suckerz- - Powering Your Launch With 300 Million Organic Views• #219 JT Barnett: The TikTok Masterclass For Brands• #223 Lauren Kleinman: The PR & Affiliate Marketing Playbook• ​​​​#243 Kian Golzari - Source & Develop Products Like The World's Best Brands-----Have any questions about the show or topics you'd like us to explore further?Shoot us a DM; we'd love to hear from you.Want the weekly TL;DR of tips delivered to your mailbox?Check out our newsletter here.Projects the DTC Pod team is working on:DTCetc - all our favorite brands on the internetOlivea - the extra virgin olive oil & hydroxytyrosol supplementCastmagic - AI Workspace for ContentFollow us for content, clips, giveaways, & updates!DTCPod InstagramDTCPod TwitterDTCPod TikTokGraham Rigby - President & CEO of American Herbal Products Association (AHPA)Blaine Bolus - Co-Founder of CastmagicRamon Berrios - Co-Founder of Castmagic

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into the significant events of 2025, a year marked by pivotal scientific breakthroughs, regulatory changes, and industry trends that have reshaped drug development and patient care.One of the standout advancements was Novo Nordisk gaining FDA approval for an oral version of Wegovy, a glucagon-like peptide-1 (GLP-1) receptor agonist for obesity management. This marks a notable shift in treatment accessibility, as it provides an easier alternative to injectables for those managing weight and cardiovascular risks. This development could significantly enhance patient adherence and broaden access to this critical therapy.However, not all news was positive. Pfizer faced a challenging situation when a patient death occurred in the extension of their Hympavzi hemophilia study. Such incidents highlight the intrinsic risks of clinical trials, especially within gene therapy realms where safety monitoring is paramount. These events remind us of the delicate balance between innovation and patient safety in advanced biologic therapies.In legal news, Johnson & Johnson was ordered by a Baltimore jury to pay $1.56 billion in a talc-related cancer case. This ruling underscores heightened scrutiny on product safety and consumer protection within the pharmaceutical industry, potentially influencing future litigation and regulatory measures.Clinical trial outcomes also presented mixed results. Neurocrine Biosciences' Ingrezza did not meet efficacy endpoints in its phase 3 trial for cerebral palsy-related dyskinesia. Although it is approved for other movement disorders, this setback reflects the complexities involved in expanding drug indications. Such challenges highlight ongoing hurdles in translating preclinical successes into clinical realities.Despite geopolitical tensions, particularly between China and the U.S., Chinese biotech firms thrived, maintaining robust deal activity. China's continued growth as an innovation hub is driven by strategic investments and collaborations that bolster global drug development efforts, underscoring its increasing influence in life sciences.Regulatory landscapes also shifted with proposals from the Center for Medicare & Medicaid Innovation to align U.S. drug prices with international rates under Medicare Parts B and D. These proposed models could significantly impact pricing strategies and market dynamics within the U.S., requiring pharmaceutical companies to adapt while ensuring equitable access to medications.Ethical challenges surfaced as six individuals were charged with insider trading involving biotech stocks. Such incidents highlight the necessity for stringent ethical standards and regulatory oversight to maintain investor confidence and market integrity.Meanwhile, AstraZeneca's extended partnership with Niowave for actinium-225 supply reflects an interest in radiopharmaceuticals as targeted cancer therapies. This collaboration highlights the potential of radiopharmaceuticals in oncology, opening promising avenues for precision medicine approaches.As 2025 closes, it's clear that this year has been one of both triumphs and trials for the pharmaceutical and biotech industries. Scientific innovations like Novo Nordisk's oral GLP-1 receptor agonist offer new hope for patients, yet challenges such as clinical trial setbacks and legal battles indicate ongoing hurdles in drug development and commercialization. These developments will likely influence industry strategies and regulatory policies as we advance into 2026.The sustained momentum of China's biotech industry amid global trade tensions remains notable. This trend reflects China's strategic investments in biotech capabilities and its growing role in global markets despite geopolitical frictions.In clinical research, Hope BioscienceSupport the show

In this episode, we delve into the latest political happenings with Congressman Scott Perry from Pennsylvania, who discusses his experiences in Congress and the challenges faced by Republicans. He shares insights on Governor Shapiro's stance on police data access and the implications of a weaponized government. Joining us later is Dr. Peter McCullough, who provides an update on the flu outbreak and innovative ways to protect yourself from illness. Finally, Scott Rasmussen shares intriguing polling data that could shape the 2026 election landscape.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Today's episode features Part 2 of our November 4 webinar, "The CFPB's Most Ambitious Regulatory Agenda Ever."  (Part 1 of this series was released on December 18. We encourage you to listen to that episode as well). In Part 2, we continue to unpack the far-reaching implications of the Consumer Financial Protection Bureau's (CFPB) regulatory ambitions. The CFPB has published a sweeping agenda that promises to reshape the landscape for consumer financial services, and our panel of seasoned attorneys offers vital context and actionable insights for industry professionals, regulators, and informed consumers alike.   Key Topics Discussed:  ·        CFPB's Pre-Rule and Long-Term Actions - What's on the regulatory horizon, including advance notices and rulemaking targets that could reshape consumer finance. ·        Clarifying "Unfair, Deceptive, and Abusive" Practices - Will the CFPB issue new rules or guidance to define these critical terms? The panel reviews statutory definitions and industry implications. ·        Identity Theft and Coerced Debt Regulation - Proposed amendments to Regulation V including new protections for survivors of identity theft and economic abuse. ·        Redefining Large Market Participants - Examination of thresholds for CFPB supervision in areas like auto financing, debt collection, consumer reporting, and international money transfers, aiming to target the largest market players. ·        Qualified Mortgage Rules & Loan Originator Compensation - What changes might be coming to mortgage rules and compensation methods, especially for small-dollar loans? The industry's wishlist and regulatory challenges are explored. ·        The Equal Credit Opportunity Act (ECOA) & Disparate Impact - Is the CFPB shifting its stance on disparate impact liability in lending? Hear the latest on the Trump administration's influence and evolving regulatory language. ·        CFPB's Withdrawal of Guidance Documents- A look at the Bureau's move away from guidance towards formal rulemaking and the impact on regulated entities. ·        Industry Feedback and Uncertainty - Lively discussion about compliance burdens, regulatory rescissions, and the ongoing uncertainty surrounding the CFPB's future funding and priorities. Meet Your Speakers from Ballard Spahr:   ·        Alan Kaplinsky (Host & Moderator): Senior Counsel and Founder and former leader of Ballard Spahr's Consumer Financial Services Group  ·        Rich Andreano, Jr.: Partner and head of the firm's Mortgage Banking Group  ·        John Culhane, Jr.: Partner in the Consumer Financial Services Group  ·        Kristen Larson: Of Counsel, Consumer Financial Services Group   ·        Daniel Wilkinson: Associate, Consumer Financial Services Group   ·        Rob Lieber: Associate, Consumer Financial Services Group   ·        Aja Finger: Associate, Consumer Financial Services Group   Tune in as our expert panel breaks down the complexities, anticipated impacts, and the road ahead under the CFPB's ambitious agenda. Consumer Finance Monitor is hosted by Alan Kaplinsky, Senior Counsel at Ballard Spahr, and the founder and former chair of the firm's Consumer Financial Services Group. We encourage listeners to subscribe to the podcast on their preferred platform for weekly insights into developments in the consumer finance industry.

Send us a textIn this episode, Dr. Mike Strouse and legal expert Lewis Walton discuss the intersection of privacy, technology, and care. They explore the implications of remote support technologies, the ownership of privacy, and the evolving landscape of healthcare. The conversation delves into the challenges and opportunities presented by new technologies, emphasizing the importance of choice and the least intrusive approaches to care. They also reflect on societal attitudes towards technology and privacy, drawing parallels with historical technological advancements.Takeaways:The conversation emphasizes the importance of privacy in care.All care methods can be seen as intrusive to some degree.Ownership of privacy is a fundamental right for individuals.Technology can enhance privacy rather than diminish it.The perception of intrusiveness varies with technology acceptance.AI and remote support are reshaping care expectations.Regulatory frameworks must adapt to new technologies.Choice in care methods is essential for individual autonomy.

Galway medtech SymPhysis Medical recently secured a $1.25m grant to support its push for US regulatory clearance and commercialisation. The firm is also looking to complete a crowd-­funding round by the end of the year. Dr Michelle Tierney, Co-Founder and Chief Scientific Officer of SymPhysis Medical joined Susan Hayes Culleton on the show to discuss.

Jon Solorzano, a partner at Vinson & Elkins, discusses how a sweeping White House executive order could drive changes to proxy advisers and shareholder proposals.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. In the ever-evolving landscape of pharmaceuticals and biotechnology, a series of strategic transactions and scientific advancements are reshaping the industry.BioMarin's acquisition of Amicus Therapeutics for $4.8 billion is a significant highlight, marking the company's largest transaction to date. This move signifies a strategic pivot towards enhancing its capabilities in the rare disease sector, leveraging Amicus's expertise and robust pipeline to potentially improve patient outcomes in this highly specialized area. This acquisition is expected to enrich BioMarin's portfolio significantly with promising assets from Amicus, reflecting a strategic shift under new leadership towards rare disease treatments.Regulatory affairs have seen considerable activity as well, with the FDA raising concerns over manufacturing practices at Catalent's gene therapy facility. These issues, documented in a Form 483 following inspections, particularly pertain to the production of Elevidys. Such regulatory scrutiny emphasizes the critical importance of maintaining compliance with manufacturing standards in gene therapy—a burgeoning field within biotech that holds immense promise for treating genetically-driven conditions.The FDA's oversight extends beyond manufacturing practices to advertising, as evidenced by an untitled letter issued to Bristol Myers Squibb regarding their Cobenfy TV ad. This action is part of the FDA's broader initiative to ensure that direct-to-consumer marketing materials accurately portray drug benefits and risks, thereby protecting public health.In another strategic move, Alvotech and Teva are gearing up for the 2026 U.S. launch of an Eylea biosimilar following a settlement with Regeneron. This development highlights the competitive dynamics within the biosimilar market—a segment poised for growth as patents on major biologics expire, offering more cost-effective alternatives and expanding treatment access.Meanwhile, Clovis Oncology has achieved a milestone with Rubraca, which transitioned from accelerated approval to full FDA endorsement for prostate cancer treatment after five years. This progression underscores Rubraca's demonstrated efficacy and safety profile in addressing advanced prostate cancer—a notable achievement amid an increasingly competitive oncology market.Policy changes proposed by Health and Human Services Secretary Robert F. Kennedy Jr. could have profound implications by disrupting funding streams for hospitals providing gender-affirming care to minors. The potential impact on healthcare providers and patients who rely on these services is significant.Turning to clinical trials, Daiichi Sankyo has seen success with Enhertu receiving FDA approval for first-line HER2-positive breast cancer treatment. Nonetheless, challenges persist as a separate phase 3 trial for another antibody-drug conjugate was paused due to unexpected patient deaths. Meanwhile, Takeda plans to seek FDA approval for its TYK2 inhibitor following successful phase 3 trials in psoriasis—indicating promising potential in autoimmune disease therapies.Strategic shifts are evident across organizations as well, highlighted by Kathy Fernando's departure from Pfizer to join Replicate Bioscience as Chief Business Officer. Her new role focuses on advancing Replicate's self-replicating RNA technology platform—an area gaining traction due to its implications for vaccine development and therapeutic applications.On the clinical trials front, Altimmune reported encouraging results from a 48-week study on metabolic dysfunction-associated steatohepatitis (MASH). Their GLP-1/glucagon dual receptor agonist demonstrated sustained weight loss and improvements in non-invasive liver fibrosis measures—offering new hope for MASH patients who face limited treSupport the show

In this episode of Legal Leaders Exchange, host Jennifer McIver sits down with Carlos Gámez of Wolters Kluwer Legal & Regulatory and Sinéad Kenny from Brightflag, to unpack the major themes that shaped the legal industry in 2025.The conversation begins with a lighthearted look at personal passions, such as BBQ rib rubs and the "Motley Accruals" band, before diving into critical industry shifts. They discuss the growing appetite for peer collaboration, the move toward data transparency between clients and law firms, and the practical realities of AI adoption.Looking ahead, they discuss predictions for 2026, debating the potential of agentic AI, the necessity of "cleaning house" regarding data infrastructure, and whether the billable hour is actually going anywhere.

In this episode of BioTalk Unzipped, hosts Gregory Austin and Dr. Chad Briscoe sit down with Glafabra CEO: Dr. Chris Hopkins, geneticist, biochemist, and biotech entrepreneur, to explore the science and strategy behind next generation cell-based gene therapies for rare diseases.With more than 25 years of experience spanning gene augmentation, rare disease biology, CRISPR licensing, and biotech formation, Dr. Hopkins shares how autologous, ex vivo engineered cell therapies may overcome key limitations of current enzyme replacement and viral gene therapies, particularly for Fabry disease.The conversation dives deep into: • How lentiviral gene augmentation in patient derived cells enables sustained enzyme production • Why redosing matters and where one time AAV therapies fall short • The scientific rationale for early intervention, including potential newborn treatment • Differences between autologous and emerging allogeneic approaches • Regulatory pathways for rare disease therapies and recent FDA developments • The role of non animal models in translational research • Montana's early access therapy law and its broader implications • Building biotech platforms amid a challenging funding environmentTopics include cell based gene therapy, Fabry disease, lentiviral vectors, stem cell engineering, rare disease drug development, regulatory science, and translational medicine. Subscribe to BioTalk Unzipped for in depth conversations with the scientists and leaders shaping the future of biomedical innovation.00:00 - Intro00:53 – Welcome to BioTalk Unzipped, Guest intro: Dr. Chris Hopkins02:10 – Guest charity: Environmental Defense Fund03:12 – His journey into rare-disease therapeutics and Glafabra05:58 – Discovering a new enzyme-deficiency therapy 06:39 – Current standard of care 07:42 – How the new autologous cell therapy works09:40 – Treating patients earlier (even newborns)10:33 – Emerging therapies - AAV gene therapy vs. cell-based therapy12:16 – Long-term results & repeat dosing14:30 – Future plans: T-cells & allogeneic approaches18:08 – New News: FDA resubmission for rare disease20:00 – Navigating FDA pathways22:06 – Non-animal testing & alternative models25:50 – Montana's early-access therapy law & medical tourism29:03 – Could other states follow?31:31 – Biotech's current funding challenges33:46 – New News: Gene therapy trial saves 4-year-old37:09 – Long-term vision for expanding therapies39:53 – Personal segment: outdoor life & skiing44:43 – Guest question on international trade Dr. Christopher Hopkinshttps://www.linkedin.com/in/christopherehopkins/ Glafabra - https://www.glafabra.com/ Environmental Defense Fund - https://www.edf.org/ Dr. Chad Briscoe

In this episode, Karl and Erum speak with Aradhita Parasrampuria, founder of CellSense, about revolutionizing the fashion embellishment industry through biology. Aradhita shares her journey from witnessing toxic dye masters in Gujarat textile factories to creating biodegradable sequins, beads, and buttons using algae and bacterial cellulose. She explains how her materials can be produced at room temperature, glow in the dark through bioluminescence, and are manufactured through an automated system that eliminates exploitative manual labor. With one in five garments containing embellishments, CellSense addresses a massive market while tackling microplastic pollution, worker health issues, and the 2027 EU ban on microbeads and lead. Aradhita discusses successful pilots with fashion brands and skincare companies, the challenges of achieving vivid colors and iridescence with biomaterials, and her vision for a circular system where anyone can upload a design and receive custom bioplastic solutions. The conversation explores the intersection of design, biotechnology, and sustainability, demonstrating how biology can create materials that don't just replace plastics—they surpass them.Grow Everything brings the bioeconomy to life. Hosts Karl Schmieder and Erum Azeez Khan share stories and interview the leaders and influencers changing the world by growing everything. Biology is the oldest technology. And it can be engineered. What are we growing?Learn more at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠www.messaginglab.com/groweverything⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Chapters:(00:00:00) - Introduction: Fungi as environmental game-changers(00:26:18) - Podcast updates and Michael Levin episode highlights(02:10:35) - Ashley Beckwith and Foray Biosciences: mining fungal biodiversity(04:57:22) - The untapped power of mycelium in biotechnology(08:04:15) - Launching the Future is Fungi Award(08:58:40) - Susanne Gløersen: Why fungi deserve to be core technology(00:12:09) - Fungi's role in solving climate, pollution, and soil degradation(00:27:06) - Quickfire questions with Susanne Gløersen(00:29:14) - Ricky Casini of Michroma: replacing synthetic food dyes with fungi(00:38:10) - Scaling fermentation capacity in South Korea(00:38:45) - Pitching fungal colorants to food manufacturers(00:40:22) - Regulatory wins and transparency in natural colors(00:41:19) - The future of fungal bio-factories in food production(00:43:05) - Scaling up production and strategic partnerships(00:44:09) - Why color matters in consumer packaged goods(00:45:46) - Winning the Future is Fungi Startup Award(00:46:59) - Quickfire questions with Ricky Cassini(00:49:02) - Dr. Britta Winterberg introduces Mycolever's clean beauty mission(00:50:00) - Fungal bio-compounds replacing petrochemicals in cosmetics(00:52:10) - Technical challenges and breakthroughs in fungal biotech(00:59:52) - Quickfire questions with Dr. Britta Winterberg(01:02:54) - Final reflections on the fungal innovation revolutionLinks and Resources:CellsenseCellsense Partnership with the United NationsBioculture Event hosted by Biofabricate x Juniper VCArahita - LinkedinMountain and The Sea - Ray Nayler 138. Living Textures, Wild Pigments: Suzanne Lee on Nature's New Aesthetic Toolbox154. No Trees Were Harmed: Symmetry Wood's Gabe Tavas on Growing Wood from WasteGrow Everything SubstackGrow Everything PatreonTopics Covered: biomaterials, fashion, embellishments, sequins, bacterial cellulose, fermentationHave a question or comment? Message us here:Text or Call (804) 505-5553 

In this Tech Talks episode, Mayer Brown partners Ana Bruder, Julian Dibbell, Gabriela Kennedy, Arsen Kourinian, and Oliver Yaros put four AI regimes head to head: the European Union's risk based Act, the United Kingdom's light touch approach, Asia's mixed models, and the United States' state by state patchwork. Their contracting playbook: lock down roles and risk, and go beyond "comply with law" to require risk management, human oversight, transparency, and data use limits. Our hosts close out by looking ahead to 2026 to see how these regimes diverge further. Show Notes:  00:04 Introductions to Artificial Intelligence Provisions in Technology Contracting 02:52 EU AI Act: Roles, Risk Tiers, and Contract Implications 04:05 UK's Pro Innovation, Light Touch Framework 07:50 Asia Snapshot: China's GenAI Rules vs. Soft Touch Regimes 10:58 U.S. Patchwork: State Laws, High Risk Use Cases, and Contracts 14:41 Negotiating AI Contracts Amid a Shifting Global Regulatory Landscape 18:44 Practical Best Practices for AI Contracting 24:50 Beyond "comply with law": Standards, Data Use, and Future Proofing 27:25 2026 Looking Ahead: Global Regulatory Trajectories

Welcome to The Adviser's What's Making Headlines podcast, your go-to source for the week's biggest stories in finance and real estate, distilled into bite-sized insights. Join host Annie Kane and commercial writer Ben Squires as they review the news of the week. This week, they discuss: The growing volume of lenders forecasting a rate hike in February. The flurry of regulatory action taken against lenders and brokers. The top brokers listed in the Elite Broker Ranking – Asset Finance, partnered by Optimise Aggregation. And much more!

In this episode, Brett Winton and Lorenzo sit down with Carlos Domingo, CEO and co-founder of Securitize, to explore how blockchain infrastructure is transforming capital markets. As a pioneer in the tokenization space, Carlos unpacks what it means to issue native securities—like stocks, bonds, and credit funds—on chain and why the modernization of legacy financial systems is long overdue. Carlos details Securitize's role as a registered transfer agent and broker-dealer, their regulatory journey with the Securities and Exchange Commission (SEC), and why native tokenization (not synthetic derivatives) is essential for future growth. They discuss the promise of 24/7 trading, peer-to-peer transfers, composability with decentralized finance (DeFi) protocols, and the global democratization of financial access—especially in markets underserved by traditional systems. The episode also dives into the tension between blockchain-native systems and financial incumbents, the logic behind Securitize's decision to go public via a special purpose acquisition company (SPAC), and the asset classes best suited for tokenization—from treasuries to public equities and beyond.Key Points From This Episode:(00:00:00) Why capital markets need a blockchain-based ledger upgrade(00:05:46) How tokenization improves global accessibility and financial user experience(00:07:35) Real-world examples: Tokenized treasury and credit funds(00:10:29) Understanding how ownership works: DTCC, transfer agents, and blockchain(00:17:08) Global appetite for tokenized stocks, following stablecoin adoption(00:18:24) Tokenizing private equity and venture capital for broader access(00:25:34) How Securitize tokenizes assets the right way—with issuer involvement(00:28:55) Regulatory clarity accelerates tokenization adoption(00:30:08) Open blockchain infrastructure unlocks composability and innovation(00:35:50) Where Securitize fits in the capital markets stack(00:37:13) Projecting tokenized assets: From $4.6B to $200B assets under management (AUM)(00:39:46) Why Securitize stays blockchain-agnostic despite protocol growth

Today's episode features Part 1 of our November 4 webinar, "The CFPB's Most Ambitious Regulatory Agenda Ever." In this packed episode, our expert panel breaks down the Consumer Financial Protection Bureau's largest and boldest regulatory agenda to date. Discussing an unprecedented lineup of 24 rulemaking items that could reshape the consumer financial services industry. What's Included: Unprecedented Regulatory Activity: We unpack why this semi-annual agenda stands out, the record number of proposed rules, and what this means for financial institutions, FinTechs, and consumers alike. Hot Topics Covered: From sweeping changes in mortgage servicing to open banking (1033 of Dodd-Frank/personal financial data rights), small business lending rules (1071 of Dodd-Frank), and the rollout of the Financial Data Transparency Act, we cover all the major initiatives and legal battles on the horizon. Industry Insight: Hear why certain rules are stirring up controversy, what compliance challenges lie ahead, and how litigation and funding woes at the CFPB might impact the pace of change. Practical Impact: Learn about technical corrections in remittance transfer rules, new standards for data sharing, and what these changes mean for day-to-day business operations. Meet Your Speakers from Ballard Spahr: Alan Kaplinsky (Host & Moderator): Senior Counsel, founder and former leader of Ballard Spahr's Consumer Financial Services Group  Rich Andreano, Jr.: Partner and head of the firm's Mortgage Banking Group  John Culhane, Jr.: Partner in the Consumer Financial Services Group  Greg Szewczyk: Chair of the firm's Privacy and Data Security Group  Mudasar Pham-Khan: Associate, Consumer Financial Services Group  Kristen Larson: Of Counsel, Consumer Financial Services Group  Daniel Wilkerson: Associate, Consumer Financial Services Group  Rob Lieber: Associate, Consumer Financial Services Group  Aja Finger: Associate, Consumer Financial Services Group  Tune in for strategic insights and practical tips to help you prepare for the CFPB's evolving rulebook. Whether you're a compliance leader, financial executive, or simply interested in how Washington's boldest moves will impact your world, this episode is your essential guide to what's next in consumer financial services. Don't miss Part 2, coming next week with even more updates and expert perspectives! Consumer Finance Monitor is hosted by Alan Kaplinsky, Senior Counsel at Ballard Spahr, and the founder and former chair of the firm's Consumer Financial Services Group. We encourage listeners to subscribe to the podcast on their preferred platform for weekly insights into developments in the consumer finance industry.

Researchers are trying to protect livestock from mountain lions. The American Farm Bureau is pleased with proposed changes in clean water regulations and will check in with a farmer of persimmons and figs to learn a little about the crop and their health benefits.   

In this episode of the AgCulture Podcast, Gregg Doud, President and Chief Executive Officer of the National Milk Producers Federation, explains how global agricultural trade negotiations actually work behind closed doors. Drawing on his experience as Chief Agricultural Negotiator at the Office of the United States Trade Representative, Gregg breaks down trade leverage, non tariff barriers, and why communication matters more than tariffs alone. He also shares why agriculture and dairy exports are central to US economic and food security. Listen now on all major platforms to hear this insider perspective on global trade!Meet the guest: Gregg Doud is President and Chief Executive Officer of the National Milk Producers Federation, where he leads efforts to strengthen US dairy competitiveness and global trade. He previously served as Chief Agricultural Negotiator at the Office of the United States Trade Representative and held senior roles in Congress and agricultural economics.What you will learn: (00:00) Introduction(06:13) Trade scale explained(13:18) China negotiations(16:01) Trade preparation(20:32) Regulatory barriers(29:13) Trade misconceptions(45:22) Closing thoughtsDiscover the world of agriculture with the "Ag Culture Podcast". This podcast will be a gateway for those passionate about agriculture to explore its global perspectives and innovative practices.Join Paul as he shares his experiences in the agricultural industry, his travels and encounters with important figures around the world.Available on YouTube, Spotify and Apple Podcasts.Subscribe at http://www.agculturepodcast.com and keep an eye out for future episodes, bringing insights and stories from the vibrant world of agriculture.

The North Carolina Medical Board is committed to providing our licensees with tools that will help them be successful in their practice. In this episode, we talk with Todd Brosius, one of the Board's Deputy General Counsel about the Board's position statements, how they are developed, and how our licensees can use them as guidance for avoiding Board discipline. Learn more here. Host: Jean Fisher Brinkley, Communications Director, North Carolina Medical BoardGuest: Todd Brosius, Deputy General Counsel, North Carolina Medical BoardProducer: Sylvia French-Hodges, Communications Specialist, North Carolina Medical BoardFollow the North Carolina Medical Board on Facebook, Instagram, LinkedIn, and X.Email your questions to: podcast@ncmedboard.org.

In this episode of The Consumer Finance Podcast, host Chris Willis is joined by Troutman Pepper Locke Partner Lori Sommerfield and Charles River Associates VP and Practice Leader of Financial Economics Marsha Courchane to discuss the current administration's "debanking" initiative established through Executive Order 14331. They discuss key actions taken by federal agencies to implement it, expectations for financial institutions and small business lenders to conduct internal reviews, regulatory reporting deadlines, and consequences for noncompliance. This episode also features practical tips on tools and technology that institutions/small business lenders can use to facilitate conducting debanking reviews and highlights the tension between the debanking initiative and financial institutions' need to comply with the Bank Secrecy Act and other federal anti-money laundering laws. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

WHAT YOU NEED TO KNOWCertification secured, enabling global shipment of HPQ's ENDURA+ lithium-ion battery cellsProduction capacity targeted at up to 1.5 million batteries per yearBattery samples delivered to prospective customers, with active commercial discussions underwayInitial battery revenue targeted for early 2026HPQ Silicon is moving from laboratory validation to real-world commercialization at a pace few early-stage battery companies achieve. CEO Bernard Tourillon outlines how a critical regulatory milestone, early customer engagement, and federal backing are converging to open near-term revenue pathways for the company's silicon-enhanced lithium-ion batteries.“Projects like HPQ Silicon's strengthen Canada's ability to manufacture components for high-performance batteries, and are creating a world-class battery ecosystem. ” – The Honourable Tim Hodgson, Minister of Energy and Natural ResourcesHPQ recently secured UN38.3 certification for its ENDURA+ 18650 and 21700 lithium-ion cells. For investors, this is not a technical footnote. UN38.3 is the global safety standard required to ship lithium batteries by air, sea, or land. Without it, commercial sales at scale are impossible.Tourillon explains that this certification clears what he calls “the logistical barrier,” allowing HPQ to move from limited sampling to meaningful customer orders and global distribution.“On our first full test run, we had no issues at all. That gives a very high level of confidence that our battery infrastructure is doing things the right way.”With certification secured, HPQ now has the ability to ship batteries in volume and support customer testing programs that lead to production orders. Management has confirmed current manufacturing capacity of approximately 1.5 million cells per year, a meaningful starting point for niche but fast-growing markets.Key commercialization signals discussed in the interview include:Battery samples already shipped to potential customersActive discussions underway with multiple prospective buyersAt least one strategic customer described as “very close” to initial ordersManagement targeting the start of battery-related revenue in early 2026Tourillon emphasized that certification timing was deliberate. Rather than rushing to market, HPQ chose to fully validate safety and quality, reducing the risk of recalls or failures that have derailed competitors.HPQ is not chasing mass-market commodity batteries. Instead, it is targeting applications where performance, longevity, and supply-chain security matter most.Discussed end markets include:E-bikes and electric mobilityDrones and specialized industrial equipmentHandheld and professional-grade power toolsStationary energy storage systems using 18650 and 21700 cellsA recurring theme in the discussion was growing interest from customers seeking non-Chinese battery supply. According to Tourillon, geopolitical risk and supply-chain concentration are driving new conversations that did not exist even two years ago.One of the more important insights for investors was HPQ's shift toward selling finished batteries rather than only supplying silicon-based anode material. Tourillon noted that margins on battery cells are expected to exceed those achievable by selling materials alone.In simple terms, HPQ captures more value by controlling the final product while keeping the option open to partner with larger manufacturers in the future.HPQ's progress is reinforced by up to $3 million in Canadian federal funding to support battery manufacturing infrastructure. Management views this as both validation and leverage, enabling the company to pursue a hybrid strategy: selling batteries directly today while retaining flexibility to license materials or partner at scale later.

Bill Gurley (@bgurley) is a general partner at Benchmark, a leading venture capital firm in Silicon Valley. His new book is Runnin' Down a Dream: How to Thrive in a Career You Actually Love.This episode is brought to you by:Momentous high-quality creatine for cognitive and muscular supportOur Place's Titanium Always Pan® Pro using nonstick technology that's coating-free and made without PFAS, otherwise known as “Forever Chemicals”Shopify global commerce platform, providing tools to start, grow, market, and manage a retail businessCoyote the card game​, which I co-created with Exploding Kittens*Timestamps:[00:00:00] Start.[00:01:43] The book that gave Jerry Seinfeld permission to pursue comedy and inspired Runnin' Down a Dream.[00:03:59] AI bubble or not?[00:06:33] Circular deals and SPV chaos.[00:12:01] Angel investing in the AI era.[00:14:32] Why you should be the most AI-enabled version of yourself, regardless of field.[00:20:47] China deep dive: Ten days, six cities, high-speed trains, and a Xiaomi SU7 factory tour.[00:22:43] Communism misconceptions.[00:25:40] Lei Jun: The Steve Jobs of China.[00:29:17] Jack Ma, ByteDance's invisible CEO, and the risks of prominence in China.[00:32:11] America vs. China (Lawyers vs. engineers).[00:41:01] Keys for US competitiveness.[00:43:47] Bill is bullish on these countries.[00:47:30] Matthew McConaughey's “Don't half ass it” moment.[00:49:45] Runnin' Down a Dream thesis: Helping people pursue X instead of A, B, or C.[00:51:03] The 80,000-hour question.[00:52:47] The self-learning test.[00:56:58] Bob Dylan as music expeditionary.[01:00:27] Go to the epicenter where the action is.[01:10:56] Danny Meyer's pivot.[01:13:30] Working for free.[01:19:37] Never too late: Tito Beveridge started Tito's Vodka at 40.[01:21:51] AI sanity checks.[01:25:59] AI-proof bets.[01:29:13] Sam Hinkie's Moneyball moment.[01:32:37] Competitive strategy, avoiding false failures, and regret minimalization.[01:43:46] Purpose, Progress, and Prosperity — the P3 Policy Institute.[01:47:18] Regulatory capture explained.[01:51:55] Why the IPO market is broken.[02:01:52] Stablecoins putting Visa and Mastercard on notice.[02:03:40] Hopes for Runnin' Down a Dream and parting thoughts.*For show notes and past guests on The Tim Ferriss Show, please visit tim.blog/podcast.For deals from sponsors of The Tim Ferriss Show, please visit tim.blog/podcast-sponsorsSign up for Tim's email newsletter (5-Bullet Friday) at tim.blog/friday.For transcripts of episodes, go to tim.blog/transcripts.Discover Tim's books: tim.blog/books.Follow Tim:Twitter: twitter.com/tferriss Instagram: instagram.com/timferrissYouTube: youtube.com/timferrissFacebook: facebook.com/timferriss LinkedIn: linkedin.com/in/timferrissSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Bank M&A isn't about speed anymore. It's about preparation.In this episode of the Travillian Next podcast, investment bankers from Janney Montgomery Scott and D.A. Davidson break down how bank M&A has become a long game shaped by diligence, culture, regulation, and timing.Travillian's Brian Love and Andrew Liesch sit down with Dan Flaherty (Janney) and Gene Katz (D.A. Davidson) to discuss how M&A conversations now happen years before a deal is signed, why diligence has become confirmatory rather than exploratory, and how cultural fit, succession planning, and regulatory strategy increasingly determine whether deals succeed or fail.The conversation also explores the role of credit unions as bank buyers, how fintech and private investors fit into today's M&A landscape, and why boards are thinking beyond short-term stock reactions when evaluating acquisitions. For bank executives, directors, and investors trying to understand where consolidation is headed, this discussion offers a realistic, on-the-ground view of what's actually driving deals today.Topics covered include:• The evolution of bank M&A diligence• Why culture is now a core deal risk• Regulatory tone and approval timelines• Succession planning and talent-driven transactions• Credit unions, fintech buyers, and market dynamics• What investment bankers expect for bank M&A in 2026

In this episode of Medsider Radio, we sat down Dr. Adam Kadlec, practicing urologist and co-founder of Rivermark Medical.Rivermark is a clinical-stage company developing FloStent, a first-line, reversible device therapy for benign prostatic hyperplasia (BPH).Before launching Rivermark, Adam built a thriving urological practice in Milwaukee and consulted for several device companies — experiences that ultimately revealed how early true device development begins and why physicians rarely get the chance to influence innovation upstream. Partnering with medtech operator Andy Doraiswamy, Adam transitioned from clinician to CEO and is now leading Rivermark through its pivotal trial.In this interview, Adam shares why workflow integration is one of the most overlooked drivers of adoption, how physician-innovators can build the right decision-making infrastructure, and why understanding who actually enrolls patients at clinical sites can make or break a trial. He also touches on the mindset required to stay resilient through the ups and downs of building a medtech startup.Before we dive into the discussion, I wanted to mention a few things:First, if you're into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You'll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and 3 packages that will help you make use of our database of 750+ life science investors more efficiently for your fundraise and help you discover your next medical device or health technology investor!In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the latest Medsider Mentors Volume VII. If you're interested, go to medsider.com/subscribe to learn more.Lastly, if you'd rather read than listen, here's a link to the full interview with Adam Kadlec.

Are you wondering what connects the nouns in the headline together?It's a Medicare cognitive screening devise. Look at these words and commit them to memory. Try to repeat back this list of words twice a day, from memory: Apple, Chair, Ocean, Book, and Clock.  During the next live edition of the popular Talk Ten Tuesday live Internet broadcast, Gloryanne Bryant will report on what some medical experts say about an inability to recall these five words.Could it be signs of cognitive changes or impairment within the brain? Or could it mean that the individual has memory and recall issues? Register now to learn more.The broadcast will also feature these instantly recognizable panelists, who will report more news during their segments:News Desk: Timothy Powell, ICD10monitor national correspondent, will anchor the Talk Ten Tuesdays News DeskThe Coding Report: Jodi Worthington, with First Class Solutions, will substitute for Christine Geiger to report on the latest coding news POV: Penny Jefferson, Manager of Coding & Clinical Documentation Integrity Services for the University of Davis Medical Center, and guest cohost of Talk Ten Tuesday, will share her point of view (POV) during the broadcast.

In this week's episode of Dollars & Sense with Joel Garris, Joel dives into two urgent questions facing American investors and retirees: How will the Corporate Transparency Act (CTA) affect your business, and are you prepared for the costly pitfalls of inherited IRA rules? First, Joel unpacks the latest developments in the Corporate Transparency Act, including an interview with Simon Conway. Listeners learn why recent rule changes and enforcement suspensions mean most U.S. companies are temporarily off the hook for beneficial ownership reporting—but why foreign entities and ongoing litigation could shift the landscape again soon. Joel and Simon highlight the burden on small businesses and the complex path to reversing these requirements. Next, Joel explores the growing crisis of Americans sacrificing retirement savings to support family members. He shares surprising statistics: While most are willing to cut back on their own lifestyles or work longer, only a small fraction are willing to reconsider family support. Joel offers practical strategies for setting boundaries, planning tax-efficient gifts, and balancing the needs of the “sandwich generation.” The episode's third segment tackles the new inherited IRA rules that could cost unwary beneficiaries thousands in penalties. Joel explains how missing required withdrawals can trigger a 25% penalty and push you into a higher tax bracket, plus the common mistakes people make and the tax-smart moves to avoid them. Key Takeaways: Stay updated on CTA regulations and know if your business is affected. Protect your retirement by setting clear boundaries on family financial support. Understand and plan for inherited IRA rules to avoid hefty penalties. Don't miss this engaging episode—click to listen and get expert insights on protecting your wealth, planning smarter, and avoiding costly mistakes! 

Whistleblower attorney Max Volman will return to the next Monitor Monday broadcast to report the latest news about whistleblowers. As we have learned, often “whistleblowers” are not insiders reporting wrongdoing; they tend to be outside the offending organization.Register now to listen to Max Voldman's exclusive report.Broadcast segments will also include these instantly recognizable features:●       Monday Rounds: Ronald Hirsch, MD, vice president of R1 RCM, will be making his Monday Rounds. ●       The RAC Report: Healthcare attorney Knicole Emanuel, partner at the law firm of Nelson Mullins, will report the latest news about auditors. ●       Legislative Update: Adam Brenman, legislative affairs analyst for Zelis, will report on the news happening at the intersection of healthcare and congressional action.●       Risky Business: Healthcare attorney David Glaser, shareholder in the law offices of Fredrikson & Byron, will join the broadcast with his trademark segment.

In this month's Maples Group Cayman Islands Regulatory 15/15 episode, Chris Capewell, Michelle Bailey, Mariana Alves and Jo Ottaway discuss the Common Reporting Standard ("CRS") 2.0, 2026 Cayman Islands Regulatory Calendar and Year End Reminders.To read the 2026 Cayman Islands Regulatory Calendar, visit https://maples.com/regulatory-round-up/2026-cayman-islands-regulatory-calendar.SPEAKERS:Chris Capewell, Partner | +1 345 814 5666 | chris.capewell@maples.com | View bioMichelle Bailey, Senior Vice President - Head of Cayman AEOIRegulatory & Compliance | +1 345 814 5711 | michelle.bailey@maples.com | View bioMariana Alves, Associate | +1 345 814 5639 | mariana.alves@maples.com | View bioJo Ottaway, Associate | +1 345 814 5511 | jo.ottaway@maples.com | View bioRESOURCES:Presentation slides: https://issuu.com/maplesgroup/docs/maples_group_15-15_podcast_-_december_2025?fr=sYjNhYzg5ODU1MzI Visit our Regulatory Round-Up Blog for the latest developments and insights in the regulatory landscapeRELATED SERVICES:Maples Group Regulatory and Financial Services AdvisoryWith a depth of experience across all regulated sectors, the Maples Group Regulatory and Financial Services team is positioned to address client needs and sensitivities. We have the largest dedicated Cayman Islands Regulatory and Financial Services team in the offshore market.Follow Us: LinkedIn: https://www.linkedin.com/company/maplesgroup/Instagram: https://www.instagram.com/maplesgroup/Twitter: https://twitter.com/maplesgroupFacebook: https://www.facebook.com/maplesgroup/Website: https://maples.com/podcasts/15-15 Blog:

Send us a textCheck us out at:  https://www.cisspcybertraining.com/Get access to 360 FREE CISSP Questions:  https://www.cisspcybertraining.com/offers/dzHKVcDB/checkoutGet access to my FREE CISSP Self-Study Essentials Videos:  https://www.cisspcybertraining.com/offers/KzBKKouvWhat happens when cybersecurity meets the engine room of the business? We dig into the partnership between the CISO and COO and show how shared risk, clear language about money, and practical tabletop drills turn security into operational resilience. Ransomware, supply chain delays, and customer impact aren't just IT issues—they're revenue issues—so we map exactly how to build alignment before a crisis hits.We break down CISSP Domain 1.5 with a plain-English tour of law categories and the statutes you actually need to know: CFAA and NIIPA for unauthorized access and critical infrastructure, FISMA and the NIST standards for federal-grade security programs, and the federal modernization that centralized oversight under DHS. Then we go deeper into intellectual property: what copyrights, trademarks, patents, and trade secrets protect; how DMCA and AI complicate ownership; and how licensing and click-through terms can quietly put your data and code at risk if you don't read them with counsel.Cross-border data is now daily business, so we unpack export controls on chips and encryption, transborder data flow obligations, and privacy regimes that carry real teeth: GDPR's 72-hour notification, China's PIPL and local representation, and state laws like CCPA that mirror EU rights. The practical takeaway is a tighter incident playbook: define “breach” with evidence-based thresholds, pre-wire stakeholder communications, and use tabletop exercises to test both technical recovery and regulatory reporting.If you're studying for the CISSP or leading a security program, this is the legal-ops blueprint you can use today. Subscribe, share this with your ops and legal teams, and leave a review to tell us which regulation gives you the biggest headache—we'll tackle it next.Gain exclusive access to 360 FREE CISSP Practice Questions at FreeCISSPQuestions.com and have them delivered directly to your inbox! Don't miss this valuable opportunity to strengthen your CISSP exam preparation and boost your chances of certification success. Join now and start your journey toward CISSP mastery today!

TLDR: It was Claude :-)When I set out to compare ChatGPT, Claude, Gemini, Grok, and ChatPRD for writing Product Requirement Documents, I figured they'd all be roughly equivalent. Maybe some subtle variations in tone or structure, but nothing earth-shattering. They're all built on similar transformer architectures, trained on massive datasets, and marketed as capable of handling complex business writing.What I discovered over 45 minutes of hands-on testing revealed not just which tools are better for PRD creation, but why they're better, and more importantly, how you should actually be using AI to accelerate your product work without sacrificing quality or strategic thinking.If you're an early or mid-career PM in Silicon Valley, this matters to you. Because here's the uncomfortable truth: your peers are already using AI to write PRDs, analyze features, and generate documentation. The question isn't whether to use these tools. The question is whether you're using the right ones most effectively.So let me walk you through exactly what I did, what I learned, and what you should do differently.The Setup: A Real-World Test CaseHere's how I structured the experiment. As I said at the beginning of my recording, “We are back in the Fireside PM podcast and I did that review of the ChatGPT browser and people seemed to like it and then I asked, uh, in a poll, I think it was a LinkedIn poll maybe, what should my next PM product review be? And, people asked for ChatPRD.”So I had my marching orders from the audience. But I wanted to make this more comprehensive than just testing ChatPRD in isolation. I opened up five tabs: ChatGPT, Claude, Gemini, Grok, and ChatPRD.For the test case, I chose something realistic and relevant: an AI-powered tutor for high school students. Think KhanAmigo or similar edtech platforms. This gave me a concrete product scenario that's complex enough to stress-test these tools but straightforward enough that I could iterate quickly.But here's the critical part that too many PMs get wrong when they start using AI for product work: I didn't just throw a single sentence at these tools and expect magic.The “Back of the Napkin” Approach: Why You Still Need to Think“I presume everybody agrees that you should have some formulated thinking before you dump it into the chatbot for your PRD,” I noted early in my experiment. “I suppose in the future maybe you could just do, like, a one-sentence prompt and come out with the perfect PRD because it would just know everything about you and your company in the context, but for now we're gonna do this more, a little old-school AI approach where we're gonna do some original human thinking.”This is crucial. I see so many PMs, especially those newer to the field, treat AI like a magic oracle. They type in “Write me a PRD for a social feature” and then wonder why the output is generic, unfocused, and useless.Your job as a PM isn't to become obsolete. It's to become more effective. And that means doing the strategic thinking work that AI cannot do for you.So I started in Google Docs with what I call a “back of the napkin” PRD structure. Here's what I included:Why: The strategic rationale. In this case: “Want to complement our existing edtech business with a personalized AI tutor, uh, want to maintain position industry, and grow through innovation. on mission for learners.”Target User: Who are we building for? “High school students interested in improving their grades and fundamentals. Fundamental knowledge topics. Specifically science and math. Students who are not in the top ten percent, nor in the bottom ten percent.”This is key—I got specific. Not just “students,” but students in the middle 80%. Not just “any subject,” but science and math. This specificity is what separates useful AI output from garbage.Problem to Solve: What's broken? “Students want better grades. Students are impatient. Students currently use AI just for finding the answers and less to, uh, understand concepts and practice using them.”Key Elements: The feature set and approach.Success Metrics: How we'd measure success.Now, was this a perfectly polished PRD outline? Hell no. As you can see from my transcript, I was literally thinking out loud, making typos, restructuring on the fly. But that's exactly the point. I put in maybe 10-15 minutes of human strategic thinking. That's all it took to create a foundation that would dramatically improve what came out of the AI tools.Round One: Generating the Full PRDWith my back-of-the-napkin outline ready, I copied it into each tool with a simple prompt asking them to expand it into a more complete PRD.ChatGPT: The Reliable GeneralistChatGPT gave me something that was... fine. Competent. Professional. But also deeply uninspiring.The document it produced checked all the boxes. It had the sections you'd expect. The writing was clear. But when I read it, I couldn't shake the feeling that I was reading something that could have been written for literally any product in any company. It felt like “an average of everything out there,” as I noted in my evaluation.Here's what ChatGPT did well: It understood the basic structure of a PRD. It generated appropriate sections. The grammar and formatting were clean. If you needed to hand something in by EOD and had literally no time for refinement, ChatGPT would save you from complete embarrassment.But here's what it lacked: Depth. Nuance. Strategic thinking that felt connected to real product decisions. When it described the target user, it used phrases that could apply to any edtech product. When it outlined success metrics, they were the obvious ones (engagement, retention, test scores) without any interesting thinking about leading indicators or proxy metrics.The problem with generic output isn't that it's wrong, it's that it's invisible. When you're trying to get buy-in from leadership or alignment from engineering, you need your PRD to feel specific, considered, and connected to your company's actual strategy. ChatGPT's output felt like it was written by someone who'd read a lot of PRDs but never actually shipped a product.One specific example: When I asked for success metrics, ChatGPT gave me “Student engagement rate, Time spent on platform, Test score improvement.” These aren't wrong, but they're lazy. They don't show any thinking about what specifically matters for an AI tutor versus any other educational product. Compare that to Claude's output, which got more specific about things like “concept mastery rate” and “question-to-understanding ratio.”Actionable Insight: Use ChatGPT when you need fast, serviceable documentation that doesn't need to be exceptional. Think: internal updates, status reports, routine communications. Don't rely on it for strategic documents where differentiation matters. If you do use ChatGPT for important documents, treat its output as a starting point that needs significant human refinement to add strategic depth and company-specific context.Gemini: Better Than ExpectedGoogle's Gemini actually impressed me more than I anticipated. The structure was solid, and it had a nice balance of detail without being overwhelming.What Gemini got right: The writing had a nice flow to it. The document felt organized and logical. It did a better job than ChatGPT at providing specific examples and thinking through edge cases. For instance, when describing the target user, it went beyond demographics to consider behavioral characteristics and motivations.Gemini also showed some interesting strategic thinking. It considered competitive positioning more thoughtfully than ChatGPT and proposed some differentiation angles that weren't in my original outline. Good AI tools should add insight, not just regurgitate your input with better formatting.But here's where it fell short: the visual elements. When I asked for mockups, Gemini produced images that looked more like stock photos than actual product designs. They weren't terrible, but they weren't compelling either. They had that AI-generated sheen that makes it obvious they came from an image model rather than a designer's brain.For a PRD that you're going to use internally with a team that already understands the context, Gemini's output would work well. The text quality is strong enough, and if you're in the Google ecosystem (Docs, Sheets, Meet, etc.), the integration is seamless. You can paste Gemini's output directly into Google Docs and continue iterating there.But if you need to create something compelling enough to win over skeptics or secure budget, Gemini falls just short. It's good, but not great. It's the solid B+ student: reliably competent but rarely exceptional.Actionable Insight: Gemini is a strong choice if you're working in the Google ecosystem and need good integration with Docs, Sheets, and other Google Workspace tools. The quality is sufficient for most internal documentation needs. It's particularly good if you're working with cross-functional partners who are already in Google Workspace. You can share and collaborate on AI-generated drafts without friction. But don't expect visual mockups that will wow anyone, and plan to add your own strategic polish for high-stakes documents.Grok: Not Ready for Prime TimeLet's just say my expectations were low, and Grok still managed to underdeliver. The PRD felt thin, generic, and lacked the depth you need for real product work.“I don't have high expectations for grok, unfortunately,” I said before testing it. Spoiler alert: my low expectations were validated.Actionable Insight: Skip Grok for product documentation work right now. Maybe it'll improve, but as of my testing, it's simply not competitive with the other options. It felt like 1-2 years behind the others.ChatPRD: The Specialized ToolNow this was interesting. ChatPRD is purpose-built for PRDs, using foundational models underneath but with specific tuning and structure for product documentation.The result? The structure was logical, the depth was appropriate, and it included elements that showed understanding of what actually matters in a PRD. As I reflected: “Cause this one feels like, A human wrote this PRD.”The interface guides you through the process more deliberately than just dumping text into a general chat interface. It asks clarifying questions. It structures the output more thoughtfully.Actionable Insight: If you're a technical lead without a dedicated PM, or you're a PM who wants a more structured approach to using AI for PRDs, ChatPRD is worth the specialized focus. It's particularly good when you need something that feels authentic enough to share with stakeholders without heavy editing.Claude: The Clear WinnerBut the standout performer, and I'm ranking these, was Claude.“I think we know that for now, I'm gonna say Claude did the best job,” I concluded after all the testing. Claude produced the most comprehensive, thoughtful, and strategically sound PRD. But what really set it apart were the concept mocks.When I asked each tool to generate visual mockups of the product, Claude produced HTML prototypes that, while not fully functional, looked genuinely compelling. They had thoughtful UI design, clear information architecture, and felt like something that could actually guide development.“They were, like, closer to, like, what a Lovable would produce or something like that,” I noted, referring to the quality of low-fidelity prototypes that good designers create.The text quality was also superior: more nuanced, better structured, and with more strategic depth. It felt like Claude understood not just what a PRD should contain, but why it should contain those elements.Actionable Insight: For any PRD that matters, meaning anything you'll share with leadership, use to get buy-in, or guide actual product development, you might as well start with Claude. The quality difference is significant enough that it's worth using Claude even if you primarily use another tool for other tasks.Final Rankings: The Definitive HierarchyAfter testing all five tools on multiple dimensions: initial PRD generation, visual mockups, and even crafting a pitch paragraph for a skeptical VP of Engineering, here's my final ranking:* Claude - Best overall quality, most compelling mockups, strongest strategic thinking* ChatPRD - Best for structured PRD creation, feels most “human”* Gemini - Solid all-around performance, good Google integration* ChatGPT - Reliable but generic, lacks differentiation* Grok - Not competitive for this use case“I'd probably say Claude, then chat PRD, then Gemini, then chat GPT, and then Grock,” I concluded.The Deeper Lesson: Garbage In, Garbage Out (Still Applies)But here's what matters more than which tool wins: the realization that hit me partway through this experiment.“I think it really does come down to, like, you know, the quality of the prompt,” I observed. “So if our prompt were a little more detailed, all that were more thought-through, then I'm sure the output would have been better. But as you can see we didn't really put in brain trust prompting here. Just a little bit of, kind of hand-wavy prompting, but a little better than just one or two sentences.”And we still got pretty good results.This is the meta-insight that should change how you approach AI tools in your product work: The quality of your input determines the quality of your output, but the baseline quality of the tool determines the ceiling of what's possible.No amount of great prompting will make Grok produce Claude-level output. But even mediocre prompting with Claude will beat great prompting with lesser tools.So the dual strategy is:* Use the best tool available (currently Claude for PRDs)* Invest in improving your prompting skills ideally with as much original and insightful human, company aware, and context aware thinking as possible.Real-World Workflows: How to Actually Use This in Your Day-to-Day PM WorkTheory is great. Here's how to incorporate these insights into your actual product management workflows.The Weekly Sprint Planning WorkflowEvery PM I know spends hours each week preparing for sprint planning. You need to refine user stories, clarify acceptance criteria, anticipate engineering questions, and align with design and data science. AI can compress this work significantly.Here's an example workflow:Monday morning (30 minutes):* Review upcoming priorities and open your rough notes/outline in Google Docs* Open Claude and paste your outline with this prompt:“I'm preparing for sprint planning. Based on these priorities [paste notes], generate detailed user stories with acceptance criteria. Format each as: User story, Business context, Technical considerations, Acceptance criteria, Dependencies, Open questions.”Monday afternoon (20 minutes):* Review Claude's output critically* Identify gaps, unclear requirements, or missing context* Follow up with targeted prompts:“The user story about authentication is too vague. Break it down into separate stories for: social login, email/password, session management, and password reset. For each, specify security requirements and edge cases.”Tuesday morning (15 minutes):* Generate mockups for any UI-heavy stories:“Create an HTML mockup for the login flow showing: landing page, social login options, email/password form, error states, and success redirect.”* Even if the HTML doesn't work perfectly, it gives your designers a starting pointBefore sprint planning (10 minutes):* Ask Claude to anticipate engineering questions:“Review these user stories as if you're a senior engineer. What questions would you ask? What concerns would you raise about technical feasibility, dependencies, or edge cases?”* This preparation makes you look thoughtful and helps the meeting run smoothlyTotal time investment: ~75 minutes. Typical time saved: 3-4 hours compared to doing this manually.The Stakeholder Alignment WorkflowGetting alignment from multiple stakeholders (product leadership, engineering, design, data science, legal, marketing) is one of the hardest parts of PM work. AI can help you think through different stakeholder perspectives and craft compelling communications for each.Here's how:Step 1: Map your stakeholders (10 minutes)Create a quick table in a doc:Stakeholder | Primary Concern | Decision Criteria | Likely Objections VP Product | Strategic fit, ROI | Company OKRs, market opportunity | Resource allocation vs other priorities VP Eng | Technical risk, capacity | Engineering capacity, tech debt | Complexity, unclear requirements Design Lead | User experience | User research, design principles | Timeline doesn't allow proper design process Legal | Compliance, risk | Regulatory requirements | Data privacy, user consent flowsStep 2: Generate stakeholder-specific communications (20 minutes)For each key stakeholder, ask Claude:“I need to pitch this product idea to [Stakeholder]. Based on this PRD, create a 1-page brief addressing their primary concern of [concern from your table]. Open with the specific value for them, address their likely objection of [objection], and close with a clear ask. Tone should be [professional/technical/strategic] based on their role.”Then you'll have customized one-pagers for your pre-meetings with each stakeholder, dramatically increasing your alignment rate.Step 3: Synthesize feedback (15 minutes)After gathering stakeholder input, ask Claude to help you synthesize:“I got the following feedback from stakeholders: [paste feedback]. Identify: (1) Common themes, (2) Conflicting requirements, (3) Legitimate concerns vs organizational politics, (4) Recommended compromises that might satisfy multiple parties.”This pattern-matching across stakeholder feedback is something AI does really well and saves you hours of mental processing.The Quarterly Planning WorkflowQuarterly or annual planning is where product strategy gets real. You need to synthesize market trends, customer feedback, technical capabilities, and business objectives into a coherent roadmap. AI can accelerate this dramatically.Six weeks before planning:* Start collecting input (customer interviews, market research, competitive analysis, engineering feedback)* Don't wait until the last minuteFour weeks before planning:Dump everything into Claude with this structure:“I'm creating our Q2 roadmap. Context:* Business objectives: [paste from leadership]* Customer feedback themes: [paste synthesis]* Technical capabilities/constraints: [paste from engineering]* Competitive landscape: [paste analysis]* Current product gaps: [paste from your analysis]Generate 5 strategic themes that could anchor our Q2 roadmap. For each theme:* Strategic rationale (how it connects to business objectives)* Key initiatives (2-3 major features/projects)* Success metrics* Resource requirements (rough estimate)* Risks and mitigations* Customer segments addressed”This gives you a strategic framework to react to rather than starting from a blank page.Three weeks before planning:Iterate on the most promising themes:“Deep dive on Theme 3. Generate:* Detailed initiative breakdown* Dependencies on platform/infrastructure* Phasing options (MVP vs full build)* Go-to-market considerations* Data requirements* Open questions requiring research”Two weeks before planning:Pressure-test your thinking:“Play devil's advocate on this roadmap. What are the strongest arguments against each initiative? What am I likely missing? What failure modes should I plan for?”This adversarial prompting forces you to strengthen weak points before your leadership reviews it.One week before planning:Generate your presentation:“Create an executive presentation for this roadmap. Structure: (1) Market context and strategic imperative, (2) Q2 themes and initiatives, (3) Expected outcomes and metrics, (4) Resource requirements, (5) Key risks and mitigations, (6) Success criteria for decision. Make it compelling but data-driven. Tone: confident but not overselling.”Then add your company-specific context, visual brand, and personal voice.The Customer Research WorkflowAI can't replace talking to customers, but it can help you prepare better questions, analyze feedback more systematically, and identify patterns faster.Before customer interviews:“I'm interviewing customers about [topic]. Generate:* 10 open-ended questions that avoid leading the witness* 5 follow-up questions for each main question* Common cognitive biases I should watch for* A framework for categorizing responses”This prep work helps you conduct better interviews.After interviews:“I conducted 15 customer interviews. Here are the key quotes: [paste anonymized quotes]. Identify:* Recurring themes and patterns* Surprising insights that contradict our assumptions* Segments with different needs* Implied needs customers didn't articulate directly* Recommended next steps for validation”AI is excellent at pattern-matching across qualitative data at scale.The Crisis Management WorkflowSomething broke. The site is down. Data was lost. A feature shipped with a critical bug. You need to move fast.Immediate response (5 minutes):“Critical incident. Details: [brief description]. Generate:* Incident classification (Sev 1-4)* Immediate stakeholders to notify* Draft customer communication (honest, apologetic, specific about what happened and what we're doing)* Draft internal communication for leadership* Key questions to ask engineering during investigation”Having these drafted in 5 minutes lets you focus on coordination and decision-making rather than wordsmithing.Post-incident (30 minutes):“Write a post-mortem based on this incident timeline: [paste timeline]. Include:* What happened (technical details)* Root cause analysis* Impact quantification (users affected, revenue impact, time to resolution)* What went well in our response* What could have been better* Specific action items with owners and deadlines* Process changes to prevent recurrence Tone: Blameless, focused on learning and improvement.”This gives you a strong first draft to refine with your team.Common Pitfalls: What Not to Do with AI in Product ManagementNow let's talk about the mistakes I see PMs making with AI tools. Pitfall #1: Treating AI Output as FinalThe biggest mistake is copy-pasting AI output directly into your PRD, roadmap presentation, or stakeholder email without critical review.The result? Documents that are grammatically perfect but strategically shallow. Presentations that sound impressive but don't hold up under questioning. Emails that are professionally worded but miss the subtext of organizational politics.The fix: Always ask yourself:* Does this reflect my actual strategic thinking, or generic best practices?* Would my CEO/engineering lead/biggest customer find this compelling and specific?* Are there company-specific details, customer insights, or technical constraints that only I know?* Does this sound like me, or like a robot?Add those elements. That's where your value as a PM comes through.Pitfall #2: Using AI as a Crutch Instead of a ToolSome PMs use AI because they don't want to think deeply about the product. They're looking for AI to do the hard work of strategy, prioritization, and trade-off analysis.This never works. AI can help you think more systematically, but it can't replace thinking.If you find yourself using AI to avoid wrestling with hard questions (”Should we build X or Y?” “What's our actual competitive advantage?” “Why would customers switch from the incumbent?”), you're using it wrong.The fix: Use AI to explore options, not to make decisions. Generate three alternatives, pressure-test each one, then use your judgment to decide. The AI can help you think through implications, but you're still the one choosing.Pitfall #3: Not IteratingGetting mediocre AI output and just accepting it is a waste of the technology's potential.The PMs who get exceptional results from AI are the ones who iterate. They generate an initial response, identify what's weak or missing, and ask follow-up questions. They might go through 5-10 iterations on a key section of a PRD.Each iteration is quick (30 seconds to type a follow-up prompt, 30 seconds to read the response), but the cumulative effect is dramatically better output.The fix: Budget time for iteration. Don't try to generate a complete, polished PRD in one prompt. Instead, generate a rough draft, then spend 30 minutes iterating on specific sections that matter most.Pitfall #4: Ignoring the Political and Human ContextAI tools have no understanding of organizational politics, interpersonal relationships, or the specific humans you're working with.They don't know that your VP of Engineering is burned out and skeptical of any new initiatives. They don't know that your CEO has a personal obsession with a specific competitor. They don't know that your lead designer is sensitive about not being included early enough in the process.If you use AI-generated communications without layering in this human context, you'll create perfectly worded documents that land badly because they miss the subtext.The fix: After generating AI content, explicitly ask yourself: “What human context am I missing? What relationships do I need to consider? What political dynamics are in play?” Then modify the AI output accordingly.Pitfall #5: Over-Relying on a Single ToolDifferent AI tools have different strengths. Claude is great for strategic depth, ChatPRD is great for structure, Gemini integrates well with Google Workspace.If you only ever use one tool, you're missing opportunities to leverage different strengths for different tasks.The fix: Keep 2-3 tools in your toolkit. Use Claude for important PRDs and strategic documents. Use Gemini for quick internal documentation that needs to integrate with Google Docs. Use ChatPRD when you want more guided structure. Match the tool to the task.Pitfall #6: Not Fact-Checking AI OutputAI tools hallucinate. They make up statistics, misrepresent competitors, and confidently state things that aren't true. If you include those hallucinations in a PRD that goes to leadership, you look incompetent.The fix: Fact-check everything, especially:* Statistics and market data* Competitive feature claims* Technical capabilities and limitations* Regulatory and compliance requirementsIf the AI cites a number or makes a factual claim, verify it independently before including it in your document.The Meta-Skill: Prompt Engineering for PMsLet's zoom out and talk about the underlying skill that makes all of this work: prompt engineering.This is a real skill. The difference between a mediocre prompt and a great prompt can be 10x difference in output quality. And unlike coding or design, where there's a steep learning curve, prompt engineering is something you can get good at quickly.Principle 1: Provide Context Before InstructionsBad prompt:“Write a PRD for an AI tutor”Good prompt:“I'm a PM at an edtech company with 2M users, primarily high school students. We're exploring an AI tutor feature to complement our existing video content library and practice problems. Our main competitors are Khan Academy and Course Hero. Our differentiation is personalized learning paths based on student performance data.Write a PRD for an AI tutor feature targeting students in the middle 80% academically who struggle with science and math.”The second prompt gives Claude the context it needs to generate something specific and strategic rather than generic.Principle 2: Specify Format and ConstraintsBad prompt:“Generate success metrics”Good prompt:“Generate 5-7 success metrics for this feature. Include a mix of:* Leading indicators (early signals of success)* Lagging indicators (definitive success measures)* User behavior metrics* Business impact metricsFor each metric, specify: name, definition, target value, measurement method, and why it matters.”The structure you provide shapes the structure you get back.Principle 3: Ask for Multiple OptionsBad prompt:“What should our Q2 priorities be?”Good prompt:“Generate 3 different strategic approaches for Q2:* Option A: Focus on user acquisition* Option B: Focus on engagement and retention* Option C: Focus on monetizationFor each option, detail: key initiatives, expected outcomes, resource requirements, risks, and recommendation for or against.”Asking for multiple options forces the AI (and forces you) to think through trade-offs systematically.Principle 4: Specify Audience and ToneBad prompt:“Summarize this PRD”Good prompt:“Create a 1-paragraph summary of this PRD for our skeptical VP of Engineering. Tone: Technical, concise, addresses engineering concerns upfront. Focus on: technical architecture, resource requirements, risks, and expected engineering effort. Avoid marketing language.”The audience and tone specification ensures the output will actually work for your intended use.Principle 5: Use Iterative RefinementDon't try to get perfect output in one prompt. Instead:First prompt: Generate rough draft Second prompt: “This is too generic. Add specific examples from [our company context].” Third prompt: “The technical section is weak. Expand with architecture details and dependencies.” Fourth prompt: “Good. Now make it 30% more concise while keeping the key details.”Each iteration improves the output incrementally.Let me break down the prompting approach that worked in this experiment, because this is immediately actionable for your work tomorrow.Strategy 1: The Structured Outline ApproachDon't go from zero to full PRD in one prompt. Instead:* Start with strategic thinking - Spend 10-15 minutes outlining why you're building this, who it's for, and what problem it solves* Get specific - Don't say “users,” say “high school students in the middle 80% of academic performance”* Include constraints - Budget, timeline, technical limitations, competitive landscape* Dump your outline into the AI - Now ask it to expand into a full PRD* Iterate section by section - Don't try to perfect everything at onceThis is exactly what I did in my experiment, and even with my somewhat sloppy outline, the results were dramatically better than they would have been with a single-sentence prompt.Strategy 2: The Comparative Analysis PatternOne technique I used that worked particularly well: asking each tool to do the same specific task and comparing results.For example, I asked all five tools: “Please compose a one paragraph exact summary I can share over DM with a highly influential VP of engineering who is generally a skeptic but super smart.”This forced each tool to synthesize the entire PRD into a compelling pitch while accounting for a specific, challenging audience. The variation in quality was revealing—and it gave me multiple options to choose from or blend together.Actionable tip: When you need something critical (a pitch, an executive summary, a key decision framework), generate it with 2-3 different AI tools and take the best elements from each. This “ensemble approach” often produces better results than any single tool.Strategy 3: The Iterative Refinement LoopDon't treat the AI output as final. Use it as a first draft that you then refine through conversation with the AI.After getting the initial PRD, I could have asked follow-up questions like:* “What's missing from this PRD?”* “How would you strengthen the success metrics section?”* “Generate 3 alternative approaches to the core feature set”Each iteration improves the output and, more importantly, forces me to think more deeply about the product.What This Means for Your CareerIf you're an early or mid-career PM reading this, you might be thinking: “Great, so AI can write PRDs now. Am I becoming obsolete?”Absolutely not. But your role is evolving, and understanding that evolution is critical.The PMs who will thrive in the AI era are those who:* Excel at strategic thinking - AI can generate options, but you need to know which options align with company strategy, customer needs, and technical feasibility* Master the art of prompting - This is a genuine skill that separates mediocre AI users from exceptional ones* Know when to use AI and when not to - Some aspects of product work benefit enormously from AI. Others (user interviews, stakeholder negotiation, cross-functional relationship building) require human judgment and empathy* Can evaluate AI output critically - You need to spot the hallucinations, the generic fluff, and the strategic misalignments that AI inevitably producesThink of AI tools as incredibly capable interns. They can produce impressive work quickly, but they need direction, oversight, and strategic guidance. Your job is to provide that guidance while leveraging their speed and breadth.The Real-World Application: What to Do Monday MorningLet's get tactical. Here's exactly how to apply these insights to your actual product work:For Your Next PRD:* Block 30 minutes for strategic thinking - Write your back-of-the-napkin outline in Google Docs or your tool of choice* Open Claude (or ChatPRD if you want more structure)* Copy your outline with this prompt:“I'm a product manager at [company] working on [product area]. I need to create a comprehensive PRD based on this outline. Please expand this into a complete PRD with the following sections: [list your preferred sections]. Make it detailed enough for engineering to start breaking down into user stories, but concise enough for leadership to read in 15 minutes. [Paste your outline]”* Review the output critically - Look for generic statements, missing details, or strategic misalignments* Iterate on specific sections:“The success metrics section is too vague. Please provide 3-5 specific, measurable KPIs with target values and explanation of why these metrics matter.”* Generate supporting materials:“Create a visual mockup of the core user flow showing the key interaction points.”* Synthesize the best elements - Don't just copy-paste the AI output. Use it as raw material that you shape into your final documentFor Stakeholder Communication:When you need to pitch something to leadership or engineering:* Generate 3 versions of your pitch using different tools (Claude, ChatPRD, and one other)* Compare them for:* Clarity and conciseness* Strategic framing* Compelling value proposition* Addressing likely objections* Blend the best elements into your final version* Add your personal voice - This is crucial. AI output often lacks personality and specific company context. Add that yourself.For Feature Prioritization:AI tools can help you think through trade-offs more systematically:“I'm deciding between three features for our next release: [Feature A], [Feature B], and [Feature C]. For each feature, analyze: (1) Estimated engineering effort, (2) Expected user impact, (3) Strategic alignment with making our platform the go-to solution for [your market], (4) Risk factors. Then recommend a prioritization with rationale.”This doesn't replace your judgment, but it forces you to think through each dimension systematically and often surfaces considerations you hadn't thought of.The Uncomfortable Truth About AI and Product ManagementLet me be direct about something that makes many PMs uncomfortable: AI will make some PM skills less valuable while making others more valuable.Less valuable:* Writing boilerplate documentation* Creating standard frameworks and templates* Generating routine status updates* Synthesizing information from existing sourcesMore valuable:* Strategic product vision and roadmapping* Deep customer empathy and insight generation* Cross-functional leadership and influence* Critical evaluation of options and trade-offs* Creative problem-solving for novel situationsIf your PM role primarily involves the first category of tasks, you should be concerned. But if you're focused on the second category while leveraging AI for the first, you're going to be exponentially more effective than your peers who resist these tools.The PMs I see succeeding aren't those who can write the best PRD manually. They're those who can write the best PRD with AI assistance in one-tenth the time, then use the saved time to talk to more customers, think more deeply about strategy, and build stronger cross-functional relationships.Advanced Techniques: Beyond Basic PRD GenerationOnce you've mastered the basics, here are some advanced applications I've found valuable:Competitive Analysis at Scale“Research our top 5 competitors in [market]. For each one, analyze: their core value proposition, key features, pricing strategy, target customer, and likely product roadmap based on recent releases and job postings. Create a comparison matrix showing where we have advantages and gaps.”Then use web search tools in Claude or Perplexity to fact-check and expand the analysis.Scenario Planning“We're considering three strategic directions for our product: [Direction A], [Direction B], [Direction C]. For each direction, map out: likely customer adoption curve, required technical investments, competitive positioning in 12 months, and potential pivots if the hypothesis proves wrong. Then identify the highest-risk assumptions we should test first for each direction.”This kind of structured scenario thinking is exactly what AI excels at—generating multiple well-reasoned perspectives quickly.User Story GenerationAfter your PRD is solid:“Based on this PRD, generate a complete set of user stories following the format ‘As a [user type], I want to [action] so that [benefit].' Include acceptance criteria for each story. Organize them into epics by functional area.”This can save your engineering team hours of grooming meetings.The Tools Will Keep Evolving. Your Process Shouldn'tHere's something important to remember: by the time you read this, the specific rankings might have shifted. Maybe ChatGPT-5 has leapfrogged Claude. Maybe a new specialized tool has emerged.But the core principles won't change:* Do strategic thinking before touching AI* Use the best tool available for your specific task* Iterate and refine rather than accepting first outputs* Blend AI capabilities with human judgment* Focus your time on the uniquely human aspects of product managementThe specific tools matter less than your process for using them effectively.A Final Experiment: The Skeptical VP TestI want to share one more insight from my testing that I think is particularly relevant for early and mid-career PMs.Toward the end of my experiment, I gave each tool this prompt: “Please compose a one paragraph exact summary I can share over DM with a highly influential VP of engineering who is generally a skeptic but super smart.”This is such a realistic scenario. How many times have you needed to pitch an idea to a skeptical technical leader via Slack or email? Someone who's brilliant, who's seen a thousand product ideas fail, and who can spot b******t from a mile away?The quality variation in the responses was fascinating. ChatGPT gave me something that felt generic and safe. Gemini was better but still a bit too enthusiastic. Grok was... well, Grok.But Claude and ChatPRD both produced messages that felt authentic, technically credible, and appropriately confident without being overselling. They acknowledged the engineering challenges while framing the opportunity compellingly.The lesson: When the stakes are high and the audience is sophisticated, the quality of your AI tool matters even more. That skeptical VP can tell the difference between a carefully crafted message and AI-generated fluff. So can your CEO. So can your biggest customers.Use the best tools available, but more importantly, always add your own strategic thinking and authentic voice on top.Questions to Consider: A Framework for Your Own ExperimentsAs I wrapped up my Loom, I posed some questions to the audience that I'll pose to you:“Let me know in the comments, if you do your PRDs using AI differently, do you start with back of the envelope? Do you say, oh no, I just start with one sentence, and then I let the chatbot refine it with me? Or do you go way more detailed and then use the chatbot to kind of pressure test it?”These aren't rhetorical questions. Your answer reveals your approach to AI-augmented product work, and different approaches work for different people and contexts.For early-career PMs: I'd recommend starting with more detailed outlines. The discipline of thinking through your product strategy before touching AI will make you a stronger PM. You can always compress that process later as you get more experienced.For mid-career PMs: Experiment with different approaches for different types of documents. Maybe you do detailed outlines for major feature PRDs but use more iterative AI-assisted refinement for smaller features or updates. Find what optimizes your personal productivity while maintaining quality.For senior PMs and product leaders: Consider how AI changes what you should expect from your PM team. Should you be reviewing more AI-generated first drafts and spending more time on strategic guidance? Should you be training your team on effective AI usage? These are leadership questions worth grappling with.The Path Forward: Continuous ExperimentationMy experiment with these five AI tools took 45 minutes. But I'm not done experimenting.The field of AI-assisted product management is evolving rapidly. New tools launch monthly. Existing tools get smarter weekly. Prompting techniques that work today might be obsolete in three months.Your job, if you want to stay at the forefront of product management, is to continuously experiment. Try new tools. Share what works with your peers. Build a personal knowledge base of effective prompts and workflows. And be generous with what you learn. The PM community gets stronger when we share insights rather than hoarding them.That's why I created this Loom and why I'm writing this post. Not because I have all the answers, but because I'm figuring it out in real-time and want to share the journey.A Personal Note on Coaching and ConsultingIf this kind of practical advice resonates with you, I'm happy to work with you directly.Through my pm coaching practice, I offer 1:1 executive, career, and product coaching for PMs and product leaders. We can dig into your specific challenges: whether that's leveling up your AI workflows, navigating a career transition, or developing your strategic product thinking.I also work with companies (usually startups or incubation teams) on product strategy, helping teams figure out PMF for new explorations and improving their product management function.The format is flexible. Some clients want ongoing coaching, others prefer project-based consulting, and some just want a strategic sounding board for a specific decision. Whatever works for you.Reach out through tomleungcoaching.com if you're interested in working together.OK. Enough pontificating. Let's ship greatness. This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit firesidepm.substack.com

REVIEW — Bob Zimmerman — European Union Space Act: Regulatory Overreach Against Private Enterprise. Zimmerman discusses a proposed European Union Space Act, characterizing this legislation as "egregious" regulatory overreach that would systematically harm private enterprise innovation and commercial space development. Zimmermanprovides a 50-word summary: Zimmerman critiques the law because the EU is attempting to impose its regulatory sovereignty on non-European companies, specifically dictating satellite construction and launch methodologies for American firms having no European operational presence or connection. Despite unprecedented opposition from the U.S. State Department, the European Space Agency, private American space companies, and the Progressive Policy Institute (a leftist policy organization), Zimmerman warns that the EU characteristically ignores substantive objections and pursues its own regulatory agenda unilaterally, functioning analogously to a Homeowners Association attempting to enforce paint color requirements on properties located in completely different cities outside their jurisdictional authority.

PREVIEW — Jeff Bliss — California Gas Prices and Regulatory Constraints. Bliss reports that while national average gasoline prices are declining due to demand weakness and ample supply, California gasoline prices remain persistently elevated, frequently exceeding $5.00 per gallon due to state-specific regulatory frameworks and the systematic closure of petroleum refineries reducing processing capacity. Bliss warns that energy market experts project California gasoline prices could catastrophically escalate to approximately $12.00 per gallon, a devastating potential price increase for a state economy structurally dependent upon private automobile transportation and individual vehicle ownership for employment, commerce, and daily economic activity.

Karl and Erum explore the untapped potential of fungi through three groundbreaking interviews. First, they speak with Susanne Gloersen, founder of the Future is Fungi Award, about why fungi represent the next frontier in biotech and how her global platform is accelerating fungal innovation across industries—from soil remediation to firefighting foam. Next, they sit down with Ricky Cassini of Michroma, winner of the Future is Fungi Award, who explains how his team engineers fungi to produce natural food colorants that outperform synthetic dyes and plant-based alternatives, offering 50x more potency than traditional options while being heat and pH stable. Finally, they interview Dr. Britta Winter of Mycolever, runner-up of the award, who discusses how her company uses fungal biodiversity to create sustainable bio-compounds for cosmetics, including emulsifiers and enhanced beauty oils that replace petrochemicals without compromising performance. Throughout the episode, the hosts highlight recent developments like MIT researchers using fungal compounds to treat brain cancer, FDA's phase-out of synthetic dyes, and the growing shift toward bio-based ingredients in food, cosmetics, and beyond.Grow Everything brings the bioeconomy to life. Hosts Karl Schmieder and Erum Azeez Khan share stories and interview the leaders and influencers changing the world by growing everything. Biology is the oldest technology. And it can be engineered. What are we growing?Learn more at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠www.messaginglab.com/groweverything⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Chapters:(00:00:00) - Introduction: Fungi as environmental game-changers(00:26:18) - Podcast updates and Michael Levin episode highlights(02:10:35) - Ashley Beckwith and Foray Biosciences: mining fungal biodiversity(04:57:22) - The untapped power of mycelium in biotechnology(08:04:15) - Launching the Future is Fungi Award(08:58:40) - Susanne Gløersen: Why fungi deserve to be core technology(00:12:09) - Fungi's role in solving climate, pollution, and soil degradation(00:27:06) - Quickfire questions with Susanne Gløersen(00:29:14) - Ricky Casini of Michroma: replacing synthetic food dyes with fungi(00:38:10) - Scaling fermentation capacity in South Korea(00:38:45) - Pitching fungal colorants to food manufacturers(00:40:22) - Regulatory wins and transparency in natural colors(00:41:19) - The future of fungal bio-factories in food production(00:43:05) - Scaling up production and strategic partnerships(00:44:09) - Why color matters in consumer packaged goods(00:45:46) - Winning the Future is Fungi Startup Award(00:46:59) - Quickfire questions with Ricky Cassini(00:49:02) - Dr. Britta Winterberg introduces Mycolever's clean beauty mission(00:50:00) - Fungal bio-compounds replacing petrochemicals in cosmetics(00:52:10) - Technical challenges and breakthroughs in fungal biotech(00:59:52) - Quickfire questions with Dr. Britta Winterberg(01:02:54) - Final reflections on the fungal innovation revolutionLinks and Resources:Future is Fungi AwardsFuture is Fungi Award WinnersThe Future is Fungi Award on LinkedInmichroma - 1st place winner Michroma partners with CJ CheilJedang to advance precision fermented colorsMycolever - 2nd place winnerXPRIZEThe language of fungi - Andrew AdamatzkyCosmetic 360 Event156. When Matter Makes Decisions: Michael Levin on the Intelligence of Form158. Mycelium On, Sound Off: How GOB's Lauryn Menard Makes Biomaterials Feel Like Culture126. Sizzling Success: Eben Bayer of MyForest Foods on Scaling Mycelium Magic46. Meat the Future: How Paul Shapiro is Brewing Superfoods at Better Meat Co.131. Leaf It to Science: How Foray Bioscience's Ashley Beckwith is Reforesting the FutureTopics Covered: mycelium, fungi, mushrooms, Future is Fungi, bioinnovation, biotech, mycoremediation, food dyes, personal care and beautyHave a question or comment? Message us here:Text or Call (804) 505-5553 

Raymond Nistor-Gallo, Kurt Zatloukal, Karin Schwenoha. Regulatory Fragmentation in Europe and Its Risks for Patient Access and Safety: Subcontracting Work Flow Steps of In-House Diagnostic Procedures. Clinical Chemistry, Volume 71, Issue 12, December 2025, Pages 1202–1211. https://doi.org/10.1093/clinchem/hvaf123

The AI boom is propelling a once-obscure group of state regulators into key decision-making roles for the economy. AI needs data centers, data centers need power and power is generally regulated in some way — depending on the state — by public utilities commissions.That's the topic of a new report from the Center on Technology Policy at NYU. Scott Brennen, CTP director and author of the report, said these commissions often make decisions on planning and permitting for new infrastructure and decide the rates utilities charge consumers.

The AI boom is propelling a once-obscure group of state regulators into key decision-making roles for the economy. AI needs data centers, data centers need power and power is generally regulated in some way — depending on the state — by public utilities commissions.That's the topic of a new report from the Center on Technology Policy at NYU. Scott Brennen, CTP director and author of the report, said these commissions often make decisions on planning and permitting for new infrastructure and decide the rates utilities charge consumers.

Andrew, Ben, and Tom discuss their takeaways from yesterday's Fed meeting and break down Oracle's earnings.Song: I Will Possess Your Heart - Death Cab for CutieFor information on how to join the Zoom calls live each morning at 8:30 EST, visit:https://www.narwhal.com/blog/daily-market-briefingsPlease see disclosures:https://www.narwhal.com/disclosure

MedboardEurope48% disruption in the EU - I hope you are all healthy: https://health.ec.europa.eu/document/download/13b2c812-b144-4489-af1f-e76af5bc97fd_en?filename=md_availability_study_presentation_2024.pdfConsultation: SCHEER asks you - Are Brain Stimulators for non-medical purpose dangerous: https://health.ec.europa.eu/consultations/scheer-public-consultation-preliminary-scientific-opinion-health-hazards-and-risks-associated-use_enQ&A Medicines used with Medical Devices - Revision 6 with new questions: https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/questions-answers-implementation-medical-devices-vitro-diagnostic-medical-devices-regulations-eu-2017-745-eu-2017-746_en.pdfEUDAMED is Mandatory - From 28 May 2026: https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=OJ:L_202502371 - https://health.ec.europa.eu/latest-updates/eudamed-four-first-modules-will-be-mandatory-use-28-may-2026-2025-11-27_enUKBetter Call MHRA - But we don't consult: https://www.gov.uk/guidance/medical-devices-get-regulatory-advice-from-the-mhraStandardISO 10993-1 mutation - Nothing is automatic anymore: https://www.youtube.com/watch?v=AkSZVNSz5a0ISO 18969 draft -  Comments until 28-01-2026: https://www.youtube.com/watch?v=zCR9HlHJ5l0EasyIFUCreate your Labels with EasyIFU - UDI included: https://easyifu.comRest of the WorldArgentinaArgentina: Simplified application - Class I/A or Class II/B: https://www.argentina.gob.ar/noticias/anmat-establece-un-regimen-simplificado-para-la-habilitacion-de-establecimientos  CanadaCanada: Modernization of the MDEL - Some changes: https://www.canada.ca/en/health-canada/services/drugs-health-products/compliance-enforcement/establishment-licences/medical-devices-compliance-bulletin/consultation-modernizing-mdel-framework-phase-ii.htmlCanada: Medical Device License Application - Guidance on how to do it: https://www.canada.ca/en/health-canada/services/drugs-health-products/medical-devices/application-information/guidance-documents/managing-applications-licenses.htmlBrazilBrazil: Digitalisation of Certificates - You can request that online now: https://www.gov.br/anvisa/pt-br/assuntos/noticias-anvisa/2025/anvisa-lanca-nova-ferramenta-para-emitir-certificados-de-dispositivos-medicosPodcastPodcast Nostalgia - Let's review previous podcastsEpisode 363 - The journey of a CRO with Helene Quie: https://podcast.easymedicaldevice.com/363-2/Episode 364 - What is changing with the new ISO 10993-1 with Marina Daineko: https://podcast.easymedicaldevice.com/364-2/Episode 365 - How to become a Lead Auditor with Rob Packard: https://podcast.easymedicaldevice.com/365-2/Social Media to followMonir El Azzouzi Linkedin: https://linkedin.com/in/melazzouziTwitter: https://twitter.com/elazzouzimPinterest: https://www.pinterest.com/easymedicaldeviceInstagram: https://www.instagram.com/easymedicaldevice

In this episode of Medsider Radio, we sat down with Andrew Holman, MD, CEO of Inmedix. Inmedix is commercializing CloudHRV, an FDA-cleared diagnostic that quantifies biological stress with clinical precision to guide treatment decisions in autoimmune disease and beyond.Andrew is a practicing rheumatologist in Seattle with 25 years of clinical and research experience. His discoveries linking autonomic dysfunction to autoimmune disease outcomes led to a $10 million patent sale to Boehringer Ingelheim. After a decade in retirement, he returned to found Inmedix and pioneer the field of immuno-autonomics — preparing the market for his technology years before launch.In this interview, Andrew shares how to build a category before commercializing a product, why clinical evidence creates competitive moats that money can't replicate, and how to raise capital from angel investors by understanding what they actually care about.Before we dive into the discussion, I wanted to mention a few things:First, if you're into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You'll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and 3 packages that will help you make use of our database of 750+ life science investors more efficiently for your fundraise and help you discover your next medical device or health technology investor!In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the latest Medsider Mentors Volume VII. If you're interested, go to medsider.com/subscribe to learn more.Lastly, if you'd rather read than listen, here's a link to the full interview with Andrew Holman.

Interview recorded - 2nd of December, 2025On this episode of the WTFinance podcast I had the pleasure of welcoming on Bill Moreland. Bill is the founder of Bankregdata.During our conversation we spoke about Bills thoughts on the credit markets, regulatory shift, risk in banks, private credit risks, large bank blowup and more. I hope you enjoy!0:00 - Introduction1:18 - Overview of credit markets7:27 - Regulatory shift24:38 - What does this mean?32:53 - Private credit44:48 - Large bank blowup53:33 - One message to takeaway?Bill Moreland is a partner in a company/website called BankRegData.com. The Austin, Texas company BankRegData started in 2010 to provide a web aggregated Federal Depository Insurance Company (FDIC) insured Bank Quarterly Call Report data and additionally offer a narrative/interpretation on the bank book dynamics (see 2016 Q4 Asset Review or Winners & Losers: Citigroup). Since 2012 this data is taken from the FFIEC Central Data Repository. FFIEC is the acronym for the Federal Financial Institution Examination Council. The FFIEC is an interagency standards committee across five banking regulators including: Federal Reserve Board of Governors , Federal Deposit Insurance Corporation, National Credit Union Administration, Office of the Comptroller of the Currency, and the Consumer Financial Protection Bureau (note the Securities Exchange Commission is not listed as one of the regulators in the FFIEC.). What BankRegData does is aggregate, and to some degree normalize, the Quarterly Call Report Data. BankRegData will get you (to a good first approximation) the distribution of securities ( deposits, mortgages, credit card accounts, loans, and tradable securities) at a quarterly aggregation level across the Banking Book of the major Bank Holding Companies.Bill Moreland - Website - https://www.bankregdata.com/main.aspX - https://x.com/BankRegDataLinkedIn - https://www.linkedin.com/in/bill-moreland-097586/WTFinance -Spotify - https://open.spotify.com/show/67rpmjG92PNBW0doLyPvfniTunes -https://podcasts.apple.com/us/podcast/wtfinance/id1554934665?uo=4LinkedIn - https://www.linkedin.com/in/anthony-fatseas-761066103/Twitter - https://twitter.com/AnthonyFatseas

The MacVoices Live! panel touches on Microsoft's warning about a risky experimental AI agent in Windows, raising concerns about big tech pushing features before security is understood. Chuck Joiner, Marty Jencius, Brian Flanigan-Arthurs, Eric Bolden, Jim Rea, Web Bixby, and David Ginsburg debate age-verification proposals from Roblox and Pornhub, explore Coinbase's new prediction market, and react to a massive WhatsApp data breach affecting billions of phone numbers.  MacVoices is supported by Incogni. Take your personal data back with Incogni! Get 60% off an annual plan at incogni.com/CHUCK and use code CHUCK at checkout..http://incogni.com/CHUCK Show Notes: Chapters: [0:00] Opening, sponsor mention, and setup for AI security discussion[0:23] Microsoft warns experimental Windows AI agent may expose user data[1:52] Enterprise perspective: why companies won't enable risky AI features[3:29] The broader question: why tech firms ship features before securing them[3:46] Roblox proposes selfie-based age verification[4:49] Pornhub urges device-level age verification by Apple/Google[6:14] State-by-state regulation pressures adult platforms[7:33] Concerns about third-party apps storing user photos and IDs[9:32] The burden of age verification and whether platforms should hold it[11:10] Regulatory inconsistencies, digital IDs, and privacy trade-offs[17:36] Coinbase launches Kaushy-powered prediction market[18:41] Risks of betting platforms built on crypto or “play money”[20:35] Similarities to opaque financial instruments and fairness concerns[21:54] Recommended podcast episodes on betting markets manipulation[24:17] WhatsApp data breach exposes 3.5B phone numbers[26:03] Why WhatsApp's identity model makes leaks so damaging[27:17] Meta's years-long failure to address systemic vulnerabilities[28:22] International reliance on WhatsApp and global impact of breach[29:58] Closing roundtable, Thanksgiving plans, and contact info Links: Critics scoff after Microsoft warns AI feature can infect machines and pilfer datahttps://arstechnica.com/security/2025/11/critics-scoff-after-microsoft-warns-ai-feature-can-infect-machines-and-pilfer-data/ Roblox demands an AI-verified selfie to prevent kids from chatting to adultshttps://www.fastcompany.com/91445273/roblox-age-verification-ai-lawsuit Pornhub Is Urging Tech Giants to Enact Device-Based Age Verificationhttps://www.wired.com/story/pornhub-is-urging-tech-giants-to-enact-device-based-age-verification/ Coinbase said to launch Kalshi-powered prediction markethttps://seekingalpha.com/news/4524123-coinbase-said-to-launch-kalshi-powered-prediction-market Against The Rules podcasthttps://www.pushkin.fm/podcasts/against-the-rules * Episode 4: “A Hard Way to Make an Easy Living” — explores how sports betting worked before legalization, the betting sharps, and differences between old-school versus online gambling.   * Episode 7: “Little Big Short” — discusses restrictions on online sportsbooks (for example in California), featuring perspectives from pastors, Native Americans, and short-sellers.   * Episode 8: “The Integrity Landscape” — covers how betting based on inside information hasn't gone away, and the problems this raises for athletes — especially in college sports.   * Episode 10: “Anybody Can Win, but Everybody's Gonna Lose…” — looks at online gambling and the risks to individuals, especially younger people; includes reflection by the host on protecting his son from gambling's lure. “ WhatsApp security flaw exposed 3.5B phone numbers – including yourshttps://9to5mac.com/2025/11/18/whatsapp-security-flaw-exposed-3-5b-phone-numbers-including-yours/ “Wanna bet? Online prediction markets wager that you will” - CBS Sunday Morninghttps://www.youtube.com/watch?v=iGx-kqf_840 Guests: Web Bixby has been in the insurance business for 40 years and has been an Apple user for longer than that.You can catch up with him on Facebook, Twitter, and LinkedIn, but prefers Bluesky. Eric Bolden is into macOS, plants, sci-fi, food, and is a rural internet supporter. You can connect with him on Twitter, by email at embolden@mac.com, on Mastodon at @eabolden@techhub.social, on his blog, Trending At Work, and as co-host on The Vision ProFiles podcast. Brian Flanigan-Arthurs is an educator with a passion for providing results-driven, innovative learning strategies for all students, but particularly those who are at-risk. He is also a tech enthusiast who has a particular affinity for Apple since he first used the Apple IIGS as a student. You can contact Brian on twitter as @brian8944. He also recently opened a Mastodon account at @brian8944@mastodon.cloud. David Ginsburg is the host of the weekly podcast In Touch With iOS where he discusses all things iOS, iPhone, iPad, Apple TV, Apple Watch, and related technologies. He is an IT professional supporting Mac, iOS and Windows users. Visit his YouTube channel at https://youtube.com/daveg65 and find and follow him on Twitter @daveg65 and on Mastodon at @daveg65@mastodon.cloud. Dr. Marty Jencius has been an Associate Professor of Counseling at Kent State University since 2000. He has over 120 publications in books, chapters, journal articles, and others, along with 200 podcasts related to counseling, counselor education, and faculty life. His technology interest led him to develop the counseling profession ‘firsts,' including listservs, a web-based peer-reviewed journal, The Journal of Technology in Counseling, teaching and conferencing in virtual worlds as the founder of Counselor Education in Second Life, and podcast founder/producer of CounselorAudioSource.net and ThePodTalk.net. Currently, he produces a podcast about counseling and life questions, the Circular Firing Squad, and digital video interviews with legacies capturing the history of the counseling field. This is also co-host of The Vision ProFiles podcast. Generally, Marty is chasing the newest tech trends, which explains his interest in A.I. for teaching, research, and productivity. Marty is an active presenter and past president of the NorthEast Ohio Apple Corp (NEOAC). Jim Rea built his own computer from scratch in 1975, started programming in 1977, and has been an independent Mac developer continuously since 1984. He is the founder of ProVUE Development, and the author of Panorama X, ProVUE's ultra fast RAM based database software for the macOS platform. He's been a speaker at MacTech, MacWorld Expo and other industry conferences. Follow Jim at provue.com and via @provuejim@techhub.social on Mastodon. Support:      Become a MacVoices Patron on Patreon     http://patreon.com/macvoices      Enjoy this episode? Make a one-time donation with PayPal Connect:      Web:     http://macvoices.com      Twitter:     http://www.twitter.com/chuckjoiner     http://www.twitter.com/macvoices      Mastodon:     https://mastodon.cloud/@chuckjoiner      Facebook:     http://www.facebook.com/chuck.joiner      MacVoices Page on Facebook:     http://www.facebook.com/macvoices/      MacVoices Group on Facebook:     http://www.facebook.com/groups/macvoice      LinkedIn:     https://www.linkedin.com/in/chuckjoiner/      Instagram:     https://www.instagram.com/chuckjoiner/ Subscribe:      Audio in iTunes     Video in iTunes      Subscribe manually via iTunes or any podcatcher:      Audio: http://www.macvoices.com/rss/macvoicesrss      Video: http://www.macvoices.com/rss/macvoicesvideorss

Today's markets lit up the precious-metals world, and we're breaking it all down. In this episode, we dive into the big surge in silver, gold, platinum, and more, and what's really driving the sudden momentum across the metals complex. But that's not all—JPMorgan just moved its entire metals-trading desk to Singapore. Why would one of the world's biggest market players shift operations halfway around the world? Regulatory pressure? Market opportunity? Strategic positioning? We'll dig into the institutional logic and what it may signal for global metals trading going forward. If you trade commodities—or just watch how capital flows shape markets—you'll want to hear this one. Listen now:

Restoring a 250-year-old farmhouse isn't just a renovation project. It's a blueprint for modern marketing.That's the lesson from Jean-Christophe Pitié, Chief Marketing and Chief Partner Officer at Contentsquare, who's spent the last five years bringing new life to a centuries-old home outside Paris. In this episode, we break down the marketing lessons hidden in his restoration journey.Together, we explore what B2B marketers can learn from blending heritage with innovation, finding creativity in constraints, and designing connected experiences where every touchpoint matters.About our guest, Jean-Christophe PitiéWith 20+ years of experience in international marketing and partner engagement, Jean-Christophe is committed to supporting companies of all sizes in their digital transformation. Passionate about technology and retail, he spent two decades at Microsoft, where he had the opportunity to contribute to the cloud transformation and to launch Microsoft 365 as well as leading Microsoft Stores. Today, as Chief Marketing and Partnerships Officer at Contentsquare, Jean-Christophe's main mission is to drive customer demand in markets around the world, continue to grow our rich partner ecosystem, and bring holistic customer experience insights to more teams worldwide.What B2B Companies Can Learn From the restoration of a French farmhouse:Honor your legacy while modernizing for today. Great brands, like great houses, balance tradition and innovation. Jean-Christophe explains, “I had architects who came initially, and they wanted to put glass everywhere, tear down some big stone walls, and I'm like, guys, this house has had oak beams for 250 years. I'm not gonna tear them down. I'm gonna keep them.” In B2B, the same logic applies. Your legacy, your history, and your customer trust are part of your brand's foundation. Don't tear them down for the sake of what's trendy. Blend your legacy with fresh, modern layers such as new tech, new storytelling, and new energy, without losing what made your brand distinct. That balance between the old and the new is what gives it lasting beauty and credibility.Constraints fuel creativity. Jean-Christophe says, “Sometimes the best projects come when… you have a constraint… either a location constraint or timing or budget, you get very creative to work around the constraints.” His farmhouse's three-foot-thick stone walls forced him to rethink how to add modern features, and that challenge sparked originality. In B2B, the same holds true. Limited budget? Shrinking timelines? Regulatory hurdles? These are the sparks for inventive ideas. Don't let your constraints kill creativity; let them focus it.Every touchpoint shapes the experience. When restoring a house, you have to look at the whole picture; every room, material, and detail needs to connect. Jean-Christophe shared, “It's a bit like your marketing strategy. You need to connect across channels… every touchpoint matters.” Just like a home's design must flow seamlessly from one room to the next, so should your brand experience, across your website, content, product, and sales. Inconsistent moments break trust. When every touchpoint feels connected and intentional, you turn friction into flow, and customers into believers.Quote“History is part of who we are, human beings… It's beautiful… It's like a brand. When you think about brand, you want something that's unique, differentiated, [and] people can relate to, which is so beautiful.”Time Stamps[00:55] Meet Jean-Christophe Pitié, Chief Marketing and Chief Partner Officer at Contentsquare[01:04] Jean-Christophe's French Farmhouse Restoration Project[04:38] Balancing Tradition and Innovation in Restoration Projects[13:56] Creative Solutions and Constraints in Restoration[21:30] Importance of Legacy[26:51] B2B Marketing Lessons from Restoring a French Farmhouse[38:30] Innovations at Content Square[43:33] Advice for CMOs on Investing in Brand[45:45] Final Thoughts and TakeawaysLinksConnect with Jean-Christophe on LinkedInLearn more about ContentsquareAbout Remarkable!Remarkable! is created by the team at Caspian Studios, the premier B2B Podcast-as-a-Service company. Caspian creates both nonfiction and fiction series for B2B companies. If you want a fiction series check out our new offering - The Business Thriller - Hollywood style storytelling for B2B. Learn more at CaspianStudios.com. In today's episode, you heard from Ian Faison (CEO of Caspian Studios) and Meredith Gooderham (Head of Production). Remarkable was produced this week by Jess Avellino, mixed by Scott Goodrich, and our theme song is “Solomon” by FALAK. Create something remarkable. Rise above the noise. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

The Annual Regulatory Oversight Report is one of FINRA's most valued resources for member firms—and this year, we're publishing it earlier than ever in response to member feedback. The 2026 Report features insights on cyber-enabled fraud, senior investor protection, generative AI, and much more. It also reflects our FINRA Forward commitment to empowering member firm compliance by sharing intelligence from across our Regulatory Operations.This episode features four FINRA leaders: Ornella Bergeron, Senior Vice President, Risk Monitoring, and Acting Head of Member Supervision; Bill St. Louis, Executive Vice President and Head of Enforcement; Feral Talib, Executive Vice President and Head of Market Oversight; and Bryan Smith, Senior Vice President and Acting Head of Strategic Intelligence. They discuss takeaways from the report, and how firms can leverage its effective practices and research to strengthen their compliance programs.Resources mentioned in this episode:2026 Regulatory Oversight ReportFINRA ForwardFINRA Crypto and Blockchain Education ProgramBlog Post: FINRA Forward's Rule Modernization—An UpdateBlog Post: Vendors, Intelligence Sharing and FINRA's MissionBlog Post: FINRA Forward Initiatives to Support Members, Markets and the Investors They ServeSEC Regulation Best Interest (Reg BI)5310. Best Execution and InterpositioningEp. 168: Investing Wisely in 2025: Avoiding Scams and Achieving Your Financial GoalsEp. 173: Vendor Vigilance: Navigating Third-Party RiskEp. 177: Previewing FINRA's Crypto and Blockchain Education ProgramEp. 180: Building Cybersecurity Resilience Through FINRA Forward Find us: LinkedIn / X / YouTube / Facebook / Instagram / E-mailSubscribe to our show on Apple Podcasts, Google Play and by RSS.

Linktree: ⁠https://linktr.ee/Analytic⁠Join The Normandy For Additional Bonus Audio And Visual Content For All Things Nme+! Join Here: ⁠https://ow.ly/msoH50WCu0K⁠Dive into the seismic Netflix-Warner Bros. Discovery deal reshaping streaming in this Analytic Dreamz segment on Notorious Mass Effect. The $72 billion acquisition merges Netflix's 300M subscribers with HBO Max's 130M, targeting 430M global users—possibly $83B including debt. Set for Q3 2026 close, it requires spinning off CNN, Discovery Channel, TBS, and TNT.Netflix scores powerhouse IPs: Batman, Superman, Wonder Woman, Harry Potter, Game of Thrones, The Sopranos, and classics like Casablanca, Citizen Kane. Columbia Business School's Kathryn Harrigan praises the unmatched library. HBO Max stays separate—no subscriber shifts yet—but co-CEO Gregory Peters signals post-close bundles, tiering, and integration amid overlap.Price hikes expected in 12-18 months. Regulatory hurdles mount: Sen. Elizabeth Warren calls it an 'anti-monopoly nightmare'; Trump administration skeptical per CNBC. Paramount-Skydance ($8.4B bid) and Comcast challenge, citing dominance risks. SAG-AFTRA warns of creative workforce threats. CEO Ted Sarandos defends: pro-consumer, pro-innovation, pro-worker, expanding choice.Warner films keep theatrical runs. Netflix also seals $1B Fort Monmouth acquisition for 12 soundstages, 500K sq ft production by 2028. Sarandos-Trump meetings add intrigue. $5.8B breakup fee if failed. Bids beat $28/share. This rivals Disney-Fox, building history's largest streaming empire. Analytic Dreamz delivers the essential analysis.Support this podcast at — https://redcircle.com/analytic-dreamz-notorious-mass-effect/donationsPrivacy & Opt-Out: https://redcircle.com/privacy

In this episode, Kyle S delivers an emergency news update on Netflix's acquisition of Warner Brothers Studios, HBO, and HBO Max for $82.7 billion. This monumental deal reshapes the entertainment landscape, merging Netflix's streaming dominance with Warner Brothers' iconic IPs like DC Comics and Harry Potter. Takeaways Netflix acquires Warner Brothers Studios, HBO, and HBO Max. The deal is valued at $82.7 billion. This acquisition reshapes the entertainment landscape. Netflix merges streaming dominance with iconic IPs. Warner Brothers' iconic IPs include DC Comics and Harry Potter. The merger faces regulatory scrutiny and shareholder approval. Netflix pledges to maintain Warner Brothers' operations until 2029. The deal accelerates Hollywood's shift to digital-first distribution. Potential impacts on creativity and content diversity are discussed. The merger could lead to significant industry changes. Sound bites Netflix acquires Warner Bros for $82.7B. Warner Bros and HBO join Netflix. Streaming landscape reshaped by Netflix's acquisition. Netflix merges with Warner Bros' iconic IPs. Regulatory scrutiny for Netflix's acquisition. Netflix pledges to maintain Warner Bros' operations. Hollywood's shift to digital-first distribution. Impact on creativity and content diversity. Significant industry changes expected. Netflix's strategic acquisition of Warner Bros. Chapters 00:00:00 - Introduction and Emergency News Update 00:01:00 - Details of Netflix's Acquisition   00:02:00 - Impact on the Entertainment Industry  

PREVIEW — Joseph Sternberg — The Failure of the "Brussels Effect." Joseph Sternberg of the Wall Street Journalcritiques the "Brussels Effect," a regulatory theory positing that heavy European Union regulatory standards would enable European companies to achieve competitive advantage through compliance-driven market dynamics. Sternbergcharacterizes this strategic approach as "total nonsense," demonstrating that EU regulatory frameworks have systematically stifled the growth of major technology startups and innovative enterprises compared to the dynamism of Silicon Valley, producing technological and economic underperformance. Sternberg reports that Brussels officials are gradually accepting this uncomfortable reality and reconsidering the regulatory framework's strategic efficacy. 1884 BRUSSELS

2/4. Politics vs. Markets: The Failures of Incentivized Climate Solutions — Terry Anderson (Editor) — Andersondiscusses adaptation barriers, noting that regulatory frameworks systematically impede Alaskan Native Villages'traditional ecological knowledge and adaptive ingenuity. Anderson critiques incentivized climate solutions, particularly carbon taxation schemes, arguing they fail fundamentally due to political polarization driven by the perverse incentive structure ("don't tax me, tax them"). Anderson advocates instead for market-driven responses that empower consumers as decision-makers, catalyzing genuine adaptation outcomes, including strategic crop relocation and agricultural practice modification in response to changing environmental conditions. 1838